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ABSTRACT
Merrill, Elaine Alice. Ph.D., Biomedical Sciences Ph.D. Program, Wright State University,
2012. A Mechanism-Based Model to Describe GABAA Receptor Trafficking and
Benzodiazepine Pharmacoresistance during Status Epilepticus.

Status epilepticus (SE) is a perplexing pathology involving a sudden and long disruption
of the brain’s normal electrical activity. The study of relevant cellular processes has been useful
in identifying therapeutic targets. As a result, many novel drugs are being studied which target
receptor systems involved in neuronal membrane excitability. Yet, the standard treatment for SE
remains benzodiazepines (BZs), a class of GABAA agonist drugs. Unfortunately, the targeted
receptors undergo a desensitization mechanism via enhanced endocytosis (receptor trafficking),
leading to rapidly reduced BZ efficacy (pharmacoresistance) within minutes of seizure onset. A
comprehensive understanding of the complex interplay between the anticonvulsant's
pharmacokinetics and its effect during SE is still lacking. Quantitative information regarding
how the trafficking mechanisms of the targeted receptor contribute to the drug's overall
pharmacodynamic profile is especially important for the development and assessment of SE
countermeasures. This is because the testing of seizure therapeutics can only be performed in
animals. Therefore computational modeling of pharmacodynamics provides a useful approach
for extrapolations to humans.
This dissertation links a physiologically-based pharmacokinetic (PBPK) model for the
therapeutic agent, with a cellular level pharmacodynamic (PD) model of the targeted receptors.
The latter explicitly takes into accounts the targeted receptor's surface expression and disrupted
trafficking during seizures and the binding of the therapeutic drug. This approach is
demonstrated for the interaction of diazepam and its major active metabolite, with the GABAA
receptor, the major therapeutic target. The GABAA receptor is known to be rapidly modulated
during seizure activity. Hypothetically, by accounting for diazepam's pharmacokinetics and
iii

occupancy of BZ-sensitive GABAA receptors, as well as the cellular trafficking of those
receptors during SE, one should be able to mathematically describe the rapid
pharmacoresistance. The model developed suggests that approximately 55% occupancy of the
original receptor number is required to reverse ongoing seizures. This is up from a reported 37%
occupancy required to prevent seizures in the rat, when diazepam is administered just before
seizure onset. The physiological basis of the model allows for extrapolation to humans and dose
optimization. In addition, the modeling approach used may serve to explain why some drugs
may be more or less effective than BZs in treating SE and to offer suggestions for alternative
therapeutics.
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Chapter 1. Introduction/Background

Status Epilepticus and Pharmacoresistance to Benzodiazepines
Continuous seizures lasting five minutes or more or distinct seizures, which occur
without complete recovery of consciousness in between, are characterized as status epilepticus
(SE). There are various causes of SE, some of which include: brain tumors or trauma, systemic
infections, metabolic disorders (high blood sugar, low sodium or low calcium), abrupt withdrawal
of alcohol or anticonvulsant drugs, organophosphate (OP) poisoning, strokes, or genetic
mutations in brain receptors. If the seizures are not controlled within a short period, brain
damage or death may occur (Sloviter, 1999; Treiman, 2007). Profound neuropathological
changes are usually detected within 20 min of the onset of seizure. This is due to hyperactivity of
N-methyl-D-aspartase (NMDA) receptors, causing increased influx of calcium (Ca2+), which
results in cell death (Lallement et al., 1993; McDonough and Shih., 1995; Leadbeater et al.,
1985). In addition, after a single episode of SE, survivors have a high risk of injury to the
hippocampus or developing epilepsy or neuropsychological dysfunction (Provenzale et al., 2008).
This is because SE can trigger epileptogenesis. Epileptogenesis is a process where after an initial
SE episode, the brain undergoes structural and functional alterations, including neuronal loss and
reorganization of neuronal circuits, in certain regions that play a key role in epilepsy, later giving
rise to spontaneous seizures. Previous studies have shown that 2 weeks after prolonged SE (> 3
hours) there is extensive loss of GABAergic interneurons in the amygdala (Tuunanen et al.,
1996). Such neuropathological changes are similar between findings from animal models of SE
and patients with temporal lobe epilepsy, especially in regards to neuronal loss in limbic
structures (Tuunanen et al., 1999).

1

One of the most common treatments for SE is the benzodiazepine (BZ) drug, diazepam.
Benzodiazepines are central nervous system (CNS) depressants. Diazepam and other BZs act on
postsynaptic GABAA receptors to enhance their function, which is to mediate fast synaptic
inhibition (Macdonald and Barker, 1978). The drug is commonly used for treating anxiety,
insomnia, seizures including SE, muscle spasms (such as in cases of tetanus), alcohol withdrawal
and Ménière's disease. It is sometimes used prior to certain medical procedures (such as
endoscopies) to reduce tension and anxiety. It possesses anxiolytic, anticonvulsant, hypnotic,
sedative, skeletal muscle relaxant, and amnesic properties (Mandrioli et al., 2008).
Diazepam is highly lipophilic and readily crosses the blood brain barrier (BBB), yielding
a rapid onset of action. It also readily crosses the placenta, and it can be transferred to milk.
Following absorption, diazepam quickly distributes throughout the body. Repeated doses can
quickly build up to high concentrations (mainly in adipose tissue) (Riss et al., 2008). Diazepam
can be administered orally (op), intravenously (iv) (requiring dilution, as it is painful and
damaging to veins), intramuscularly (im) or as a suppository. When administered orally, it is
rapidly absorbed and has a fast onset of action (5-10 minutes). The onset of action is 1–5 minutes
for intravenous (iv), 15–30 minutes for im and approximately 10 minutes for rectal administration
(Riss et al., 2008). Diazepam has several pharmacologically active metabolites. The main active
metabolite of diazepam is desmethyldiazepam (also known as nordazepam or nordiazepam).
Diazepam's other active metabolites include temazepam and oxazepam. These compounds are
considered minor metabolites as they are conjugated with glucuronide, and quickly excreted
primarily in the urine. Because the metabolites are centrally active, the serum values of diazepam
alone are not always useful in predicting the effects of the drug, especially from repeated doses.
Diazepam has a biphasic half-life of about 1–3 and 2–7 days for the active metabolite
desmethyldiazepam (Riss et al., 2008).
In cases of OP poisoning, it has been shown that a combination of atropine and diazepam
are more effective in reducing mortality than atropine or diazepam alone. Diazepam should be
2

given to patients poisoned with OPs whenever convulsions or pronounced muscle fasciculations
are present. The recommended dose in cases of OP poisoning is 5-10 mg iv in the absence of
convulsions and 10-20 mg iv in cases with convulsions, which may be repeated as required
(Antonijevic and Stojilkovic, 2007). To protect against potential nerve agent (NA) exposures,
military personnel are provided with “convulsion antidote to nerve agent” (CANA) injectors,
which are im injection canisters containing 10 mg of diazepam, designated for administration into
the thigh muscle, upon the appearance of fasciculation or convulsions. While im is a convenient
way to administer the drug in field conditions, absorption of the drug by this route is often slow,
erratic and incomplete (Abbara et al., 2009).
Unfortunately, the efficacy of diazepam to abolish seizures diminishes rapidly with time
after the onset of SE, often necessitating the need for more aggressive anticonvulsants to be used.
Studies have shown that the diazepam doses found to be effective either before or a few minutes
after seizure onset may be less than effective for terminating ongoing seizure/convulsive activity.
For example, Shih et al., (1997) found that approximately a six-fold greater dose of diazepam was
required to terminate seizure activity (when administered 5 min after seizure onset) than when
given 30 min prior to soman challenge, as a pretreatment. Similarly, Walton and Treiman (1996)
achieved 100% efficacy with diazepam when pilocarpine-induced seizures were treated quickly
after onset, with less success the longer seizure progressed. The rapid loss of anticonvulsant
effect with increasing duration of SE is associated with internalization of BZ-sensitive GABAA
receptors and a slight increase in localization of BZ-insensitive GABAA receptors to the synaptic
membrane (Naylor et al., 2005; Goodkin et al., 2005; Feng et al ., 2008). Hence, the synapses
mediated by the GABAA receptor are altered dramatically, resulting in a loss of BZ efficacy. The
receptor desensitization differs from the gradual down regulation of target receptors known as
tolerance, seen with chronic use of a drug. Here, the desensitization mechanism of the targeted
GABAA receptor, appears to be membrane activity dependant and ligand independent.
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GABAA Receptor Composition
Neuronal inhibition is of paramount importance in maintaining a balance with dynamic
excitatory signals in the central nervous system. Gamma-aminobutyric acid A (GABA)
represents the most widely distributed inhibitory neurotransmitter in the central nervous system
(CNS). When GABA is released, it binds to two main types of molecular receptors: fast-acting
ionotropic GABAA/GABAC receptors and slower acting metabotropic GABAB receptors
(Borman, 2000), with GABAA being the predominant type. It has been estimated that 20-50% of
all CNS synapses contain GABAA receptors (Nutt, 2006). The neurons upon which these
receptors reside are mostly interneurons and therefore uniquely able to alter the excitability of
local circuits within a given brain region (Mohler et al., 2004).
GABAA receptors are ligand-gated ion channels. Once activated by GABA, the receptor's
central channel opens, generally allowing Cl- influx, hyperpolarizing the cell membrane, resulting
in neuronal inhibition. However, the effect of activating these receptors depends on the
electrochemical gradient for Cl- on the postsynaptic membrane (Macdonald and Olsen, 1994). In
the nervous system of adult animals, the extracellular Cl- concentration is typically maintained
higher than the intracellular Cl- concentration by the K+/Cl- cotransporter (Rivera et al., 1999).
Therefore, activation of the GABAA receptors, typically, results in Сl- entry into the neuron,
hyperpolarizing the cell membrane and diminishing the change of a successful action potential
from occurring. In immature hippocampal neurons, the cotransporter is absent and therefore
intracellular Cl- is higher and activation of the GABAA receptor, depolarizes the neurons,
increasing its chance of triggering an action potential (Rivera et al., 1999). GABA, like most
synaptically released neurotransmitters, often saturate their corresponding post synaptic receptors
(Clements, 1996). Therefore, the most effective means of modulating the plasticity of
postsynaptic response, be it hyperpolarizing or depolarizing, is to change the density and/or
composition of surface receptors on the neuron
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Each GABAA receptor is composed of five subunits (Figure 1-1). This heteropentameric
Cl- channel is selected from 18 known subunits existing in mammals. The 18 subunits can be
divided into seven classes, of which some have multiple members: α(1-6), β(1-3), γ(1-3), δ, ε(13), π, and θ. Alternative splicing of some receptor mRNAs (Jacob et al., 2008) increases
structural diversity further. Hence, multiple combinations of the 18 subunits are possible.
Remarkable receptor heterogeneity exists, with subtype combinations varying in different brain
regions and cell types, and during different times in ontogeny (Luscher and Keller, 2004).
However, the vast majority of GABAA receptor subtypes are composed of the following five
subunits: two α (α1or α2) and two β (β2 or β3) in combination with either a γ (mainly γ2) or δ
(Figure 1-1) (Jacob et al., 2008). It is believed that γ and δ subunits cannot co-exist in the same
receptor (Rudolph and Mohler, 2006).

Figure 1-1. The GABAA receptor structure is composed of five subunits from seven subunit
subfamilies (α, β, γ, δ, ε, θ and π), forming a heteropentameric Cl– channel. Most GABAA
receptors expressed in the brain consist of two α subunits, two β subunits and one γ subunit; the γ
subunit can be replaced by δ, ε, θ or π. Two GABA molecules bind at the interfaces between the
α and β subunits and trigger the opening of the channel, allowing the rapid influx of Cl– into the
cell. BZ binding occurs at the interface between the α (1, 2, 3 or 5) and γ subunits and
potentiates GABA-induced Cl– flux. Reprinted by permission from Macmillan Publisher
Ltd:[Nature](Jacob et al., 2008).

Subunit composition is very important as it determines the receptor subtypes’ distinct
pharmacological properties and cellular localization. The subunit composition also appears to
5

determine the channel’s kinetics of phasic and tonic activation and can influence its
desensitization (Bianchi et al., 2001). Phasic and tonic activation refer to both spatially and
temporally unique modes of inhibition in which GABAergic transmissions shape neural activity
(Mody, 2001). Phasic, or synaptic, inhibition is believed to result from high GABA concentration
transients acting on synaptic GABAA receptors composed of two α subunits (usually α1-α3 or
α5), two β subunits, and a γ subunit (Farrant and Nusser, 2005). Phasic receptors respond rapidly
to stimulus change, producing action potentials proportional to the rate of change of the stimulus.
Therefore the phasic response of the neuron diminishes very quickly and then stops until another
dramatic rate change. They do not respond to sustained stimulus. In this way they do not provide
information on the duration of the stimulus; instead they convey information on rapid changes in
stimulus intensity and rate. In contrast, tonic inhibition arises from low ambient “overflow”
GABA acting on extrasynaptic GABAA receptors containing two α4 or α6 subunits with two β
subunits and a δ subunit (Mody, 2001; Farrant and Nusser, 2005). Tonic receptors adapt slowly
to stimuli, continuing to fire as long as the stimulus is maintained. They convey information
about the duration or presence and intensity of a stimulus. Some tonic receptors are permanently
active and indicate a background level (Santhakumar et al., 2006).
The β subunits appear to be critical for functional cell surface expression and therefore
are likely to be components of all receptor subtypes (Connolly et al., 1999). With exception of
the β subunits, the distinct differences in subunit compositions, mentioned above, indicate that
synaptic and extrasynaptic GABAA receptors have different sensitivities to BZs. A major
property of the γ2 subunit is to bestow diazepam sensitivity to subtypes containing the α subunits,
mentioned above. The BZ binding site is proposed to lie at the interface between the α and γ2
subunits, with residues from each subunit contributing to the binding site (Smith and Olsen,
1995). Therefore receptors composed of “synaptic” α1, α2, α3, and α5 subunits together with β
and γ subunits are BZ-sensitive and are predominantly located within the postsynaptic membrane,
with the exception of α5, which is localized extrasynaptically (Fritschy et al., 1998) (Figure 1-2).
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Most extrasynaptic α5, γ2-containing GABAA receptors, contribute to tonic inhibition modulated
by diazepam (Glykys et al., 2008) and regulate the excitability of pyramidal cells (Bonin et al.,
2007). Consequently, postsynaptic and extrasynaptic receptors formed with α1-3,5 and γ2
subunit are diazepam-sensitive and contribute to the pharmacological profile of classical BZ-site
agonists. The γ2 subunit, which is present in the vast majority of GABAA receptor subtypes, is
also required for postsynaptic clustering of GABAA receptors, by interacting with gephyrin, a
cytoskeletal protein selectively concentrated in GABAergic and glycinergic synapses in the CNS.
Gephyrin plays a crucial role in anchoring the GABAA receptors in the synaptic cleft (Luscher
and Keller, 2004). By contrast, those GABAA receptors composed of “extrasynaptic” subtypes
(α4 and α6 together with β and δ subunits) are a specialized population that mediate tonic
inhibition and are BZ-insensitive (Figure 1-2).

Figure 1-2. Localization of surface GABAA receptors. GABAA receptors composed of α (1–3)
subunits together with β and γ subunits are thought to be primarily synaptically localized,
whereas α5βγ receptors are located largely at extrasynaptic sites. Both these types of GABAA
receptors are BZ-sensitive. By contrast, receptors composed of α(4 or 6)βδ are BZ-insensitive
and localized at extrasynaptic sites. Reprinted by permission from Macmillan Publisher Ltd:
[Nature](Jacob et al., 2008).
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Alterations of GABAA Receptor expression during SE
The density and composition of GABAA receptor subunits within the neuronal
membranes change rapidly during the course of SE. The changes are reflected by the selfsustaining nature of seizures in SE, and the fact that BZs are effective during the early time
course of SE but loose potency by 30 min (Kapur and Macdonald, 1997; Treiman et al., 2007).
During SE there is increased neuronal hyperexcitability, miniature inhibitory post-synaptic
currents (IPSCs) are reduced and the number of GABAA receptors per dentate granule cell is also
rapidly decreased (Goodkin et al., 2005). Clathrin-dependent GABAA receptor internalization
has been identified as one of the mechanisms involved in this process (Jacob et al., 2008). The
events triggered promote a decrease in PKC and PKA activity, resulting in reduced
phosphorylation of β3 subunits. The decreased phosphorylation of β3 promotes the interaction
between the receptor and the clathrin-adaptor protein 2(AP2) (Figure 1-3), which is involved in
recruitment of GABAA into clathrin-coated pits and its removal from the plasma membrane
(Goodkin et al., 2008). The involvement of PKC-mediated phosphorylation in regulating
GABAA receptor trafficking and in effect, synaptic efficacy, has been demonstrated in several
studies (Connolly et al., 1999; Brandon et al., 1999). These dynamic processes profoundly affect
the strength of GABAergic signaling, neuronal inhibition, and presumably synaptic plasticity.
In vitro studies in hippocampal neurons using low magnesium to promote spontaneous
epileptiform discharges demonstrate large reductions in GABA-gated chloride currents that
correlate with reductions in GABAA receptors (Blair et al., 2004). Additionally, GABAA receptor
endocytosis has been identified as an early event in the ischemic response that leads to
excitotoxicity and cell death (Mielke and Wang, 2005). In vivo studies using chemoconvulsants
have shown that the rapid reduction in the number of BZ-sensitive GABAA receptors in granule
cells correlates with a reduction in the level of β2/β3 and γ2 immunoreactivity present in the
vicinity of a presynaptic marker (Naylor et al., 2005). While there is a reduction in the BZ8

sensitive receptors (of α1-3, 5 with β2/β3 and γ2 subunits), extrasynaptic GABAA receptor
subunits (α4 and δ), have been reported to increase in rat models of temporal lobe epilepsy (TLE)
(Fritschy et al., 1998). It is important to note that receptors composed of α4 and δ subunits are
BZ-insensitive. In addition, heritable diseases that affect receptor trafficking have been recently
recognized and compelling evidence exists that mechanisms underlying SE and acquired epilepsy
involve GABAA receptor internalization (Bradley et al., 2008). For example, similar alterations
in GABAA receptor subunit expression patterns noted in hippocampal tissues from humans with
TLE (Treiman DM. 2007).

Figure 1-3. Schematic of GABAA receptor trafficking. GABAA receptors are synthesized and
assembled in the Endoplasmic Reticulum (ER) and matured in the Golgi and reach the surface
outside of synapses through the secretory path. Synaptic receptors reach their destination
through lateral movement in the plasma membrane, where they mediate phasic inhibition.
Phosphorylation affects receptor function and removal from the surface through clathrin
mediated endocytosis, by enhancing binding with scaffolding proteins, which stabilize receptors
at the post synaptic membrane. From the ER, receptors are either recycled or degraded in
lysosomes or through proteasomes after ubiquitylation. (Figure taken directly from Tretter and
Moss, 2008).
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Use of physiologically-based pharmacokinetic/ pharmacodynamic modeling to analyze
pharmacoresistance
As discussed previously, the rapid pharmacoresistance to BZs, seen with increasing
duration of SE appears to be highly dependent upon the rapid kinetics of BZ-sensitive GABAA
receptors surface expression (Naylor et al., 2005; Goodkin et al., 2005; Feng et al., 2008).
Therefore, with specific regard to finding novel therapeutics for preventing or ameliorating NAinduced SE, the role that GABAA receptor dynamics together with diazepam pharmacokinetics
play in the drug’s rapid pharmacoresistance with time after seizure onset deserves further
quantitative and mechanistic investigation. Physiologically-based pharmacokinetic/
pharmacodynamic (PBPK/PD) modeling is one way to integrate various data sets to
quantitatively assess such interactions.
Physiologically based pharmacokinetic modeling is a mathematical technique for
predicting the absorption, distribution, metabolism and excretion (ADME) of a chemical/drug in
humans and other animal species. The models are mechanistic by mathematically incorporating
the anatomical and physiological structure of the body, as well as physical and biochemical
descriptions of the drug involved in the complex ADME processes. The model structures are
multi-compartmental, with compartments corresponding to specific tissues, interconnected by
blood or lymph flows. Differential equations can then be written to describe the changing
distribution of the chemical, being studied, in each compartment, using parameters representing
actual blood flows, pulmonary ventilation rates, and tissue volumes. These models are typically
validated against in vivo data in animal species. However, the inclusion of measured
physiological parameters makes PBPK models very suitable for extrapolations across species
(e.g., rat to humans) and dose routes (e.g., iv and im). The capacity for such extrapolations makes
PBPK models especially suited for estimating and optimizing the efficacy of anticonvulsants,
especially antidotes against OP-induced SE. Most studies that measure efficacy of NA antidotes
examine biomarkers of exposure and the antidotes’ impact on them, such as lethality, cell death,
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oxidative stress, etc. However, measuring the dose of the therapeutic agent actually reaching a
target tissue (i.e., brain) cannot be directly scaled from animal studies and is very important to
ensure efficacy. The extrapolation of results from in vitro and animal studies to humans is a basic
problem in pharmacological studies. For most drugs, preclinical trials are followed by clinical
human trials that corroborate and fine tune the data. But, in the case of assessing therapeutics for
exposures to OPs, the problem is especially critical since human toxicity data are not readily
available. It is certainly possible to determine the dose of various BZs or other therapeutics that
result in no adverse effects in human. But, determining their protective efficacies against seizures
induced by OPs have to be estimated based on animal experiments only.
Pharmacodynamic (PD) models predict the time course of the drug’s effect on the body,
through the application of mathematical modeling of the mechanism of action involved at the
cellular level. These models are typically validated with in vitro data. In this case, the PD model
describes the changing surface expression of GABAA receptors during on-going seizures, which
can then be linked with PBPK predictions of the target dose of the anticonvulsant drug via the
receptor occupancy theory. The model primarily focuses on the dynamics of GABAA receptor
trafficking and does not include mechanistic details of downstream elements, such as Ras or
mitogen-activated protein kinase (MAPK). Detailed analysis of receptor trafficking can be well
understood in the context of a whole cell model using ordinary differential equations (ODEs).
ODE models arise from the description of processes where quantities of interest are changing
with respect to time. Linking PBPK and PD models of a drug allow for the prediction of the
subsequent temporal pattern of in vivo pharmacological response (Figure 1-4).
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Figure 1-4. Linking diverse data sets through PBPK/PD modeling

Thesis Plan
The primarily focus of this thesis is to demonstrate an approach for integrating a wide
variety of experimental data into a quantitative framework that can be used to extrapolate the
efficacy of a particular therapeutic agent against SE. In particular, four specific objectives are
performed:
1. Modeling GABAA receptor trafficking under both basal and SE conditions (PD model),
2. Modeling the pharmacokinetics of diazepam (PBPK model),
3. Linking the models (PBPK/PD),
4. Extrapolating to humans and optimizing therapeutic window.
Coding of the model was written in ACSLX™ (Advanced Continuous Simulating
Language Xtreme, Version 2.4), a software environment for modeling, simulation and analysis of
nonlinear systems and processes. The following chapters describe the development and
validation of the model components. The final model can be used to make predictions regarding
the response (seizure termination) in humans to specific doses of diazepam during SE and
identifying an optimal therapeutic dose. In addition, the model may potentially serve as an
approach for evaluating similar therapeutics and for generating mechanistic hypotheses for which
studies can be designed to test.
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Chapter 2. Modeling GABAA Receptor Trafficking

Introduction
It is well known that the functional strength, of GABAergic synapses, changes in
proportion with the number of postsynaptic GABAA receptors (Otis et al., 1994; Nusser et al.,
1997). Observations that GABAA receptor expression rapidly diminishes following enhanced
activity and ischemia underscore the importance of quantitatively understanding the mechanisms
regulating the receptor’s endocytosis. The trafficking of GABAA receptors has not been modeled
previously. This chapter attempts to incorporate what is known regarding the regulation of
GABAA receptor surface expression (the α1β2/3γ2 subtypes) into a quantitative whole cell PD
model which can be used to simulate the rapid trafficking of the receptor during homeostatic and
SE conditions. Later in Chapter 4, the cellular PD model is linked with a PBPK model for
diazepam to understand the impact on diazepam's overall pharmacodynamic profile and to predict
the pharmacoresistance seen during SE. The receptor model may serve to better understand the
potential contribution that novel therapeutic targets within the endocytic pathway could play in
alleviating SE.

Processes involved in GABAA Receptor trafficking
The density of synaptic GABAA receptors is in part determined by the exchange of
synaptic and extrasynaptic surface receptors while the total number of surface receptors is
determined by the rates of internalization, synthesis, recycling and insertion into the plasma
membrane (Figure 1-3). Internalization of GABAA receptors is in part regulated by clathrinmediated endocytosis (Kittler et al., 2000; Herring et al., 2003). Clathrin is a specialized protein
that forms coated pits at the membrane surface, which recruit and concentrate receptors for
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internalization. GABAA receptors are recruited to clathrin-coated pits via the interaction of the
adaptor protein (AP2) with the β and/or γ subunits of the GABAA receptor complex (when it is
dephosphorylated) and with clathrin. Finally, as more receptors are incorporated into the pit, it
progressively invaginates until dynamin pinches off the vesicle from the plasma membrane
(Kittler et al., 2005). Endocytosis occurs predominantly at peri- and extrasynaptic sites, where
clathrin is located.
Following endocytosis the receptor undergoes either recycling to the plasma membrane
or degradation. Trafficking of new receptors to the cell surface involves posttranslational
modification and maturation through the secretory pathway. The localization of nascent receptors
in either synaptic or extrasynaptic regions of the plasma membrane is dictated by receptor subunit
composition and other factors, guiding insertion. Once at the cell surface, the receptor may move
laterally between the post- and extra-synaptic regions and is subject to both constitutive and
regulated endocytosis.

Model Development and Parameterization
To model the movement of major BZ-sensitive GABAA receptor subtypes (α1β1-3γ2), a
simple whole cell model was developed, similar to those developed by Lauffenburger and
Linderman (1993) and Earnshaw and Bressloff (2006) for other receptors. The model consists of
a series of ODEs describing receptor movement between compartments for the postsynaptic
membrane and the internal cytoplasmic region of a single inhibitory synapse on a dendrite shaft
(Figure 2-1). The postsynaptic surface membrane consists of two compartments representing the
post synaptic density (PSD) region and the extrasynaptic membrane (ESM) of the remaining
dendrite spine head and neck. Like most synaptic receptors, within the ESM region, GABAA
receptors diffuse freely within the membrane. However, within the PSD, the movement of
GABAA receptor is more restrained by binding of the β and γ subunits to scaffolding proteins,
namely gephyrin (Goodkin et al., 2008; Jacob et al., 2005). GABAA receptors are internalized
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mainly from the ESM, via endocytosis (Bogdanov et al., 2006). Once internalized, the receptors
undergo endosomal sorting and are either recycled to the cell surface or delivered to lysosomes
for degradation. Rate constants are assigned to each of these major constitutive cycles between
membrane and intracellular compartments.

ESM

PSD
ka

Rb

kb

kc

Rf

RESM

kd
kin

kex

Rin
kdeg

vsyn

Figure 2-1. Simplified model of GABAA receptor trafficking. Rb and Rf represent surface

GABAA receptors within the PSD that are either bound to scaffolding proteins or free,
respectively. RESM represents extrasynaptic GABAA receptors and Rin represent
internalized receptors. First order rates are used to describe binding (kb) and unbinding
(ka) of receptors to scaffolding proteins within the PSD, lateral movement between the
synaptic and extrasynaptic membrane (kc and kd), internalization (kin), recycling and
membrane insertion (kex) and degradation (kdeg). Synthesis of nascent receptors is
described with a zero order rate, Vsyn.
The symbols and values of parameters selected to describe GABAA receptor trafficking
are listed in Table 1.1. To begin parameterization, experimentally measured values for receptor
densities were assigned to each compartment of the model. For simplicity, these values are
expressed as a number of receptors per post synaptic dendrite spine, thereby treating the dendrite
spine much like a whole cell. Using a combined approach of patch-clamp recordings and
quantitative immunogold localization, Nusser et al., (1997) estimated post-synaptic GABAA
receptor numbers in cerebellar stellate cells. They reported that synaptic density is fairly constant
at about 1250 functional GABAA receptors per um2, corresponding to an estimated average of 26
receptors within the PSD area, which is in the range of 0.01 - 0.1 um2. A common feature of
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synaptic receptors is that they enter and exit synapses through lateral diffusion (Lévi and Triller,
2006). This behavior implies that synaptic receptor numbers may be regulated by movements of
extrasynaptic receptors and that pools of extrasynaptic and synaptic receptors are in a dynamic
equilibrium. Changes to this equilibrium will alter the amount of receptors present at the
synapse. Lévi and Triller also reported that the movement of receptors in or out of synapses also
transits through a tiny perisynaptic region (400 nm) where they remained for a longer period than
expected from their lateral diffusion coefficient in the extrasynaptic plasma membrane. Hence,
diffusion within synapses is confined and likely reflects interactions with scaffolding proteins,
setting specific kon and koff values for the receptors binding to gephyrin, in the case of GABAA
receptors. Movement of receptors within the synaptic region has been measured for some
receptors. For example, approximately 45% of the synaptic glycine receptors are estimated to be
highly mobile while the remaining 55% are restricted (Lévi and Triller, 2006). Such values were
not available for GABAA receptors. However, based upon measured lateral movements between
extrasynaptic and synaptic regions, which are discussed later, a higher percentage of synaptic
GABAA receptors appear to be restricted. Bogdanov et al., (2006) reported that approximately
19% of synaptic GABAA receptors are associated with AP2, which recruits them into clathrin
coated pits. Therefore, it is possible that the remaining 81% or less of the synaptic GABAA
receptors is restricted by interaction with gephyrin or other structural proteins. For the purposes
of this model it is assumed that the fraction of synaptic GABAA receptors that are less mobile is
similar to that of glycine receptors. Therefore, assuming 26 receptors occur at the synapse during
equilibrium, 11.7 would be free (Rf) and 14.3 would be bound (Rb). Comparing the postsynaptic
with extrasynaptic GABAA receptor labeling, it has been reported that 24.6 ± 6.4% of surface
GABAA receptor clusters are opposed to synapsin (Bogdanov et al.; 2006). Synapsins are a
family of proteins involved in regulating the release of vesicles of neurotransmitters from the
presynaptic button. Hence they are located directly across the synaptic cleft from the
postsynaptic membrane. From the reported percentage of receptors opposed to synapsin (24.6%),
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it can be estimated that approximately 75% of surface GABAA receptors (~79.7 receptors) are
extrasynaptic (RESM), giving an estimated 105.7 receptors on the surface (Rs). In terms of
receptors per surface area, greater density occurs at the postsynaptic region. However, given that
the extrasynaptic region accounts for approximately 98% of the spine’s membrane surface area,
whereas the postsynaptic region accounts for approximately 2%, a greater total number of
GABAA receptors exist within the extrasynaptic region (Nusser et al., 1995; Lévi and Triller,
2006).
The internal receptor density (Rin) was derived from primary brain cell cultures from 7day chick embryos using [3H]flunitrazepam as an irreversible photoaffinity label for BZ-sensitive
GABAA receptors (Czajkowski and Farb, 1989). They found 80% of the labeled GABAA
receptors were sensitive to trypsin cleavage and were therefore on the surface, whereas 20% were
insensitive, being either intracellular and/or membrane sequestered. Therefore, assuming
approximately 105.7 receptors are at the surface, the number of internal receptors is estimated to
be approximately 26.4.
The ODEs, solving for each compartment within the model shown in Figure 2-1 can be
written as:
Equation (2.1)

Equation (2.2)

Equation (2.3)

Equation (2.4)

The concept of steady state (SS) is a mathematical idealization of pseudo homeostasis, which
plays an important role in kinetic modeling. A system is in steady state if the concentrations of
the compartments do not change, which means the corresponding ODEs are zero. A general
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steady state analysis of constitutive receptor trafficking can be performed, using only the model
structure and estimated receptor densities, without knowing the rate constants for a particular
reaction. When all the rates (accounting for binding, lateral movement, internalization,
recycling/exocytosis, synthesis and degradation of receptors) arrive at steady state, we can derive
the following system of algebraic equations.
Equation (2.5)

Equation (2.6)
Equation (2.7)

Equation (2.8)
Taking equation (2.8) into equation (2.6) yields:

Equation (2.9)

Taking equation (2.9) into (2.3):
Equation (2.10)
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Equation (2.11)
Finally, equation (2.11) into (2.4) yields:
Equation (2.12)

Equation (2.13)

From the SS analysis, we can estimate the proportional differences in rate constants to be
kb/ka ≈ 1.22, kd/kc ≈ 0.14, kex/kin ≈ 3.02, and Vsyn/kdeg ≈ 26.4 receptors/dendritic spine, based upon
receptor density values listed in Table 2-1. These ratios were initially applied and resulting
simulations were compared to experimental data on GABAA receptor trafficking. The following
sections describe more explicitly how the final rate constants were derived from quantitative in
vitro studies, taking care to simulate the data in accordance with the particular experimental
design used. For example, in studies where receptors are prelabeled at 4°C and their
internalization is turned on at 37°C and measured at designated time points, the internal pool of
receptors (Rin) is initialized with a value of zero. In other words, no internal receptors are labeled
at time zero. In comparison, when surface receptors are labeled at each time point, it can be
assumed that the change in surface expression reflects not only the loss of labeled surface
receptors to endocytosis, but also the reappearance of new or recycled receptors into the
membrane via exocytosis, which then become labeled. Such studies reflect all of the endocytic
processes occurring simultaneously, with exception of those studies where a chemical or protein
is used to enhance or “block” a particular pathway.
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Table 2-1. GABAA Receptor Trafficking Model Parameters
Parameter (units)
Rf (R/dendritic spine)
Rb (R/dendritic spine)
RESM (R/dendritic spine)
Rin (R/dendritic spine)
ka (h-1)
kb (h-1)
kc (h-1)
kd (h-1)
kin (h-1)

Basal
11.7
14.3
79.7
26.4
1.0
1.22
1.0
0.14, 0.18
0.9, 1.0

SE
*
*
*
*
2.0
1.22
2.0
0.14
6.0

Data References
Nusser et al. 1997; Lévi and Triller, 2006
Nusser et al. 1997; Lévi and Triller, 2006
Nusser et al. 1995, 1997; Jacob et al., 2005
Czajkowski and Farb, 1989
Bogdanov et al., 2006
Bogdanov et al., 2006
Bogdanov et al., 2006
Bogdanov et al., 2006
Kanematsu et al., 2007; Connolly et al., 1999;
Goodkin et al., 2008; Blair et al., 2004
Cinar et al., 2001, Joshi and Kapur, 2009
Kittler et al., 2005; Borden and Farb, 1988
SS analysis

Kex (h-1)
2.7, 7.0
3.02
kdeg (h-1)
0.28a
0.28a
Vsyn (R/dendritic spine/h)
7.39
7.39
Notes:
All rate constants initially derived via SS analysis, then optimization to referenced data.
Where more than one value is given, the red value represents final value used in model
Parameters are color coded, as described below in order of confidence, with 1 being the
highest:
1. Green – derived from neuronal cultures (final values used in model)
2. Blue - derived from recombinant cell lines (not used in final model)
3. Purple – values used derived from studies on glycine receptors, due to lack of
data on GABAA receptors
4. Red – value based on SS analysis alone, no supporting time course data
available.
a
Value derived from one time point.
*Receptor densities change with time from onset of seizure

Basal Conditions

Constitutive Endocytosis
GABAA receptors on the surface of cortical neurons at steady state undergo significant
constitutive endocytosis. Trafficking of the β2/3 and γ subunit-containing receptors is swift,
occurring in a time scale of minutes (Kittler et al., 2000; Goodkin et al., 2005; Bogdanov et al.,
2006). Previous studies have revealed that 17-25% or more of the total cell-surface receptor
population, depending on maturity of neurons, are internalized within 15 min at steady state
(Kittler et al, 2005). For the purposes of this model, the rate of internalization (kin) was optimized
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from experimental data by Katamatsu et al. (2007) and Connolly et al. (1999) (Figure 2-2).
Katamatsu and colleagues performed a constitutive receptor internalization assay using human
embryonic kidney 293 (HEK293) cells transiently co-expressed with GABAA receptor
α1myc/β2myc/γ2Smyc subunits. In their experiment, cells were pulse-labeled with radioactive
[35S/35S]cysteine/methionine for 4 h, followed by labeling surface receptors with anti-myc
antibody on ice prior to chase experiment for up to 4 h at 37°C. The myc-tagged receptors were
then precipitated with protein G-Sepharose beads, followed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and autoradiography for quantification of remaining myctagged surface receptors. To simulate this data, as shown in Figure 2-2a, it was assumed that only
the surface level of GABAA receptors were fully equilibrated with the anti-myc antibodies in
initial conditions. Therefore, the simulation was initialized using the basal level of surface
GABAA receptors and zero internal receptors. The decreasing radioactivity, relating to myctagged receptors, with chase time, suggest that surface receptors prelabeled with the antibody
were constitutively internalized and delivered to the lysosome where they were degraded
(Kanematsu et al. 2007).
Connolly et al. (1999) also analyzed the membrane stability of recombinant α1β2γ2
receptors in HEK cells. Cells were prelabeled as described in Figure 2-2 and surface expression
was measured up to 2 h.

From these data, kin value was optimized to fit the amount of remaining

surface GABAA receptors (Rs) as shown in Figure 2-2, yielding a value of 0.9 h-1. The data from
the two studies are very similar, but suggest slightly different rates of internalization. While both
utilized the same receptor subunit compositions, within the same cell type, the slight divergence
may reflect differences in methods.
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Figure 2-2. Constitutive endocytosis of GABAA receptors. Model simulation (lines)vs. measure
surface levels of GABAA receptors as a percent of baseline (solid squares. Data taken from A)
pulse-chase analysis (at times indicated) for surface GABAA receptors in HEK293 cells,
containing the α1β2γ1 subunit receptor composition (X ± SEM, n=3) (Kenamatsu et al., 2007), B)
immunolabelled GABAA receptors in A293 cell expressing α1β2γ2. All subunits were 9E10tagged prior to incubation at 37 °C for up to 120 min. Surface receptor levels were quantified
using iodinated anti-myc (9E10) antibody and expressed as a percentage of level detected at time
zero (X ± SD, n=3) (data from Connolly et al. 1999).

Studies measuring intracellular accumulation of GABAA receptors in HEK cells and in
cultured neurons were then used to fit the exocytosis rate, kex, as time course of cytosolic
accumulation of labeled receptors reflect both the internalization rate and exocytosis, as well as
degradation. Cinar et al. (2001) used to HEK 293 cells, transfected with the α1β2γ23x9E10 subunit,
to quantify internalized receptors (data shown in Figure 2-3). No endocytic processes were
blocked in this study. Therefore, with kin set to the value established from the above studies and
the initial amount of internal receptors set to zero, kex was fit to the second phase of the curve with
a value of 7.0 h-, resulting in the simulation shown in Figure 2-3.

22

Percent Internalized

10

5

0
0.0

0.1

0.2

0.3

0.4

0.5

0.6

Hours

Figure 2-3. Model simulation (line) vs. measured (squares) percent of surface GABAA receptors
internalized in HEK cells transfected with α1β2γ23x9E10 or α1β2S3x9E10γ2 subunits. Receptors were
labeled with 125I-labeled c-Myc(9E10) antibody and placed in fresh medium at 37°C for the times
shown. Cells were then stripped at pH 1.5 and extracts and stripping medium were counted. The
125
I associated with stripped cells is expressed as a percentage of the total activity per well,
corrected for binding to cells held continuously at 4°C. (X ± SE, n=3) (data from Cinar et al.,
2001).

Intracellular accumulation of GABAA receptors was also measured by Joshi and Kapur
(2009). However, rather than using HEK cells, these researchers compared intracellular
accumulation of the δ and γ2 subunits in cultured hippocampal neurons using an antibody feeding
technique. They found that internalization of the γ2 subunit was faster than that of the δ subunit.
Intracellular accumulation of the δ subunit peaked between 3–6 h, whereas, maximum
internalization of the γ2 subunit took 30 minutes. The interest here is in using their data to
compare rate constants of neuronal γ2-containing GABAA receptors with recombinant forms. It
is notable that the percent internalized at one hour in this study, 35±9% (n=4), is over three times
higher than that measured by Cinar et al., 2001. The kex:kin ratio estimated by SS analysis was
approximately 3.02. In figure 2-4, optimized values of kin = 1.0 and kex=2.7 (an approximate ratio
in agreement with SS analysis values), were found to simulate the data reasonably well. These
observations suggest that GABAA receptors in neurons undergo a similar rate of constitutive
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endocytosis as that of recombinant receptors expressed in HEK293 cells; however the rate of
exocytosis in the neuron is slower.

Percent Internalized

40
35
30
25
20
15
10
5
0
0.0

0.2

0.4

0.6

0.8

1.0

Hours

Figure 2-4. Model simulation (line) vs. measured data (squares). Intracellular accumulation of
the γ2 subunit in organotypic hippocampal slice cultures, expressed as a ratio of intracellular to
surface γ2 (X ± SD, n=4). Intracellular accumulation of the γ2 subunit was studied using a
biotinylation assay (data from Joshi and Kapur, 2009).

Degradation of GABAA Receptors
Upon internalization, receptors are subjected to either rapid recycling or targeted for
lysosomal degradation. This endosomal sorting of internalized receptors does not occur
instantaneously, but over longer periods of time. It is reported that within 6 h 29% of originally
internalized receptors are degraded in lysosomes (Kittler et al., 2005). That value is in agreement
with data from Borden et al. (1984), which suggest that approximately 24% of receptors are
degraded within 6 h. To establish the degradation rate, kdeg, an experimental scenario is assumed
where surface receptors are in full equilibrium with a radiolabel and allowed to internalize and be
degraded. Because the amount degraded in the model is represented by the integration of kdeg x
Rin, the initial number of internal receptors (Rin 0) is set to zero before initiating the integration.
Then the fraction of receptors degraded equals the amount degraded over the original number of
surface receptors. The value of kdeg was then fitted with an approximate value of 0.28 h-1 to yield
between 24 and 29% of labeled receptors being degraded within 6 h (Figure 2-5).
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Figure 2-5. Simulation (line) of the degradation of BZ-sensitive GABAA receptors.

Lateral diffusion of surface GABAA Receptors between synaptic and extrasynaptic regions.
In addition to constitutive endocytosis and recycling, GABAA receptors also undergo
significant rates of lateral movements, which can directly modulate the efficacy of synaptic
inhibition (Chen et al, 2007). Lateral diffusion within the plane of the plasma membrane has
been demonstrated for almost all excitatory and inhibitory receptors, including GABAA.
Fluorescence recovery after photobleaching (FRAP) techniques on green fluorescent protein
(GFP)-tagged GABAA receptors, has been used to demonstrate that synaptic receptors exhibit
lower lateral mobility compared to the extrasynaptic receptors (Luscher and Keller, 2001). The
mechanisms behind receptor accumulation at the synaptic site are not well defined. But this
effect is at least in part due to clusters of the scaffolding protein, gephyrin, which acts to restrict
movement of inhibitory receptors within the postsynaptic membrane (Jacob et al., 2005; Luscher
and Keller, 2001).
To further understand the movement of receptors to and from synapses, Bogdanov et al.
(2006) developed tools to visualize GABAA receptor endo- and exocytosis in addition to their
accumulation at synaptic sites by creating receptor subunits modified with N-terminal pHluorin
reporters, capable of binding α-bungarotoxin (Bgt) with high affinity. Using Bgt derivatives they
revealed that the principal sites of both GABAA receptor endo- and exocytosis are extrasynaptic
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in hippocampal neurons. In addition, they demonstrated that newly inserted extrasynaptic
receptors are capable of directly accessing synaptic sites. Therefore, synaptic GABAA receptors
are derived directly from their extrasynaptic counterparts, and constitute a dynamic mechanism
for neurons to rapidly modulate receptor number at inhibitory synapses by controlling the
availability and stability of extrasynaptic receptors.
To quantify this apparent loss of extrasynaptic receptors, Bogdanov et al. measured RdBgt staining in 1–2 mm2 areas of interest representing synaptic receptors and extrasynaptic
receptors that were at least 2 μm from the nearest synapses and within the same neuron. The ratio
of extrasynaptic-to-synaptic Rd-Bgt staining (Bgt-Extrasynaptic/Bgt-Synaptic) was then
determined and ratios at zero time were given an arbitrary value of 1.0. This ratio decreased
rapidly with duration of incubation at 37°C, reaching a steady state at 1 h (Figure 2-6). This
demonstrates that extrasynaptic GABAA receptors containing pHBBSβ3 have much shorter
residence times on the cell surface as compared to synaptic receptors. To determine whether the
time-dependent loss of extrasynaptic receptors represents their preferential endocytosis, the
authors preincubated hippocampal neurons expressing pHBBSβ3 subunits for 1 h with 50 mM
myristoylated membrane-permeable p4 peptide (M-p4), a potent inhibitor of GABAA receptor
endocytosis (Kittler et al, 2000, 2005) before labeling with Bgt. M-p4 appeared relatively
effective at blocking the loss of extrasynaptic receptors, that is seen in the untreated neurons
(controls) (Figure 2-6), and therefore the time-dependent decrease in Bgt-Extrasynaptic/BgtSynaptic ratio seen in controls (Figure 2-6).
Here, their data was used to validate rates of lateral movement between extrasynaptic and
synaptic regions (kc and kd) within our model. Using values developed from the SS analysis, as
well as validated parameters, the model did not predict the shift of receptors from extrasynaptic to
synaptic regions (shown by the dashed line in Figure 2.6). Care was taken to replicate
experimental conditions by initializing internal receptor density at zero and turning off the
internalization rate (kin = 0) to simulate the data from the endocytosis blocking experiment (e.g.,
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M-p4 block pretreatment). Interestingly, the SS values predicted a steady state between the
measured Bgt-Extrasynaptic/Bgt-Synaptic ratio with endocytosis blocked. The data suggest that
either endocytosis is not completely blocked by M-4 or there is a shift toward the synaptic
regions. By increasing kd from 0.14 to 0.18, the simulations improved.

Extrasynaptic/Synaptic

1.2

1.0
M-p4 (blocks endocytosis)

0.8

0.6

0.4
0.0

Controls

0.3

0.6

0.9

1.2

1.5

1.8

Hours

Figure 2-6. Model simulations (lines) vs. data (squares, X ± SD) of movement of synaptic
receptors to extrasynaptic region. Data shown expressed as a fraction of baseline
extrasynaptic/synaptic ratio for control conditions (reds line and lower data) or after 1 h
pretreatment with M-p4, which blocks endocytosis (black lines and upper data)The dash lines
indicate SS parameters, the solid lines indicate an increase of kd. (Data from Bogdanov et al.,
2005).

Enhanced endocytosis during SE
The expression of BZ-sensitive GABAA receptors following pilocarpine-induced SE in 47 week rats (40 mg/kg im) was assessed by Naylor et al. (2005). After 1 h from the onset of stage
5 seizures (Racine, 1972), they cultured brain slices and estimated that the dentate granule cells
had a 50% decrease of the number of physiologically active GABAA receptors per granule cell
synapse (based upon mIPSC analysis) and a 69 and 76% reduction, respectively, of the number of
β2/β3 and γ2 subunit-like immunoreactivity in the vicinity of the presynaptic marker,
synaptophysin. It was suggested that the lower estimate obtained from mIPSC analysis compared
with immunocytochemistry may be explained by normalization of synaptic physiology with
incubation after slice preparation (which arrests seizures). A corresponding increase in β2/β3 and
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γ2 subunit-like immunoreactivity in the cytoplasm suggests that the subunits relocate to the cell
interior during SE, possibly through endocytosis or decreased recycling to the surface. This loss
of physiologically active receptors was mimicked by a 20 min exposure of slices to GABA,
suggesting that an increase in GABA release with seizure activity may be a contributing factor.
The reduction of synaptic GABAA receptors may characterize the key transition in which the
potent intrinsic mechanisms that usually stop seizures fail and SE becomes self-sustaining. Of
note, the time course for the loss of BZ responsiveness, which fails between 10 and 45 min of SE
(Kapur and Macdonald, 1997), parallels the emergence of self-sustaining SE in the lithiumpilocarpine model. Furthermore, a loss of inhibition exceeding 30%, as assessed by paired-pulse
inhibition, is predicted to result in spontaneous seizures (Kapur and Lothman, 1989).

Modeling GABAA Receptor Trafficking during SE
To parameterize the model to simulate changes in GABAA receptor surface expression
during SE, data from in vitro seizure models performed on dissociated hippocampal neurons and
hippocampal slice cultures, was used. Epileptiform activity can be induced in neuronal cultures
from virtually all epilepsy-sensitive brain regions by levating extracellular potassium
concentration (K+o) The induction coincides with membrane depolarization and blockade of
evoked synaptic transmission. It is the result of reduced surface charge screening and reduced
Ca2+-dependent K+ currents. Activation of NMDA receptors and other glutamate receptors are
enhanced. This effect is readily mimicked in vitro by raising K+o in ACSF from 3.0-3.5 mM
(standard in most laboratories) to 7.5 mM or higher (Jensen and Yaari, 1988).
Seizure-like events can also be induced by omitting Mg2+ from artificial cerebrospinal
fluid (ACSF). Induction of this activity depends on increased neuronal excitability resulting from
reduced surface charge screening (which increases neuronal excitability), facilitated transmitter
release, and activation of NMDA receptors due to removal of the Mg2+ block of NMDA receptoroperated ion channels.
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These approaches were used by Goodkin et al. (2008) and Blair et al. (2004) to study
GABAA receptor internalization during SE-like conditions. Interestingly, the measured
internalization rates from the two studies were consistent, despite the use of different in vitro SE
models. In addition, the reduction in surface GABAA receptor internalization also agrees that
measured in rat hippocampus at 1 h after onset of pilocarpine-induce seizures (Goodkin et al.,
2008). Given their consistency and agreement with in vivo data, the data from these two studies
were use to establish parameters for simulating receptor dynamics during SE. Blair and
colleagues used hippocampal cultures treated with low Mg2+ to simulate epileptic neurons. The
neurons were pre-labeled with β2/3 antibodies at 4°C and then fixed and immunohistochemically
analyzed after incubation at 37°C. Goodkin et al. (2008) measured the surface expression of the
γ2 and δ subunits in hippocampal slice cultures incubated in an 10 mM KCl external medium for
5 min, 15 min, 30 min or 60min before fixation and antibody tagging of the γ2 subunit using a
primary antibody directed against the N terminus of that subunit. The following paragraphs
discuss how the data from these studies were used to parameterize the model for SE conditions.
As described earlier, enhance endocytosis and reduced phosphorylation of the β subunit,
resulting in increased lateral mobility, are key components in the rapid internalization of the
GABAA receptor seen during SE. Therefore the parameters that most obviously would be altered
upon SE are the rates of endocytosis, kin, and the on-rate of binding to gephyrin, kb.
The data from Goodkin et al. (2008) is simulated in Figure 2-7. Here the GABAA
receptors were labeled after fixation at the given time points. Hence, the change in expression of
surface GABAA receptors (Rs(t)) represents the culmination of all processes occurring
simultaneously. The basal kin and other SS values simulated the control data. To simulate the
increased level of internalization seen under high external KCl, increasing kin to 6 h-1 improved
the fit, but lowering kb had little effect on the simulation. Therefore an increase in lateral
movement from the synaptic region to the extrasynaptic regions was examined, resulting in an
optimized kc value of 2 h-1 (Figure 2-7).
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Figure 2-7. Model simulation (lines) vs. measured percent surface expression (X ±SEM) of
GABAA receptor γ2 subunits(squares)in dissociated hippocampal cultures after incubation in
standard or 10[KCl]o medium for the indicated times. After incubation cultured neurons
werefixed and antibody tagged for the γ2 subunit. Each time point pooled from 15 neuronal
processes (3 replicates) (Goodkin et al., 2008).

In the study by Blair et al. the receptors were pre-labeled before surface level of receptors
was measured. Therefore in simulating their data, the internal receptor density was initialized
with a value of zero. The control data was simulated with basal SS values, from Table 2-1.
Interestingly, with all other parameters set at SS basal values, it was found that the same increase
in the kin and kc values, which were optimized to Goodkin et al.’s data, also simulated endocytosis
under low Mg2+ conditions (Figure 2-8). However, while only one timepoint was provided in
Blair’s study, the fact that the same model parameters describe receptor internalization from both
studies, provides confidence in the model’s ability to predict change surface expression during
SE.
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Figure 2-8. Model simulation (line) vs. measured data (squares)(X ± SD) of increased
endocytosis in low Mg2+ treated hippocampal cultures. Viable control and epileptic neurons
prelabeled with β2/3 antibodies at 4°C and then fixed at 0 and 1 h after incubation at 37°C for
immunohistochemical analysis (n=4, p 0.001). (Data from Blair et al., 2004.)

Sensitivity Analysis of Parameters
To identify important parameters associated with the surface expression of GABAA
receptors and the model’s behavior, a parameter sensitivity analysis was performed. Using the
finalizing basal parameters, the model was repeatedly run for 1h to determine the total number of
surface receptors (Rs). The total number of surface receptors was selected, as it is an endpoint
used in Chapter 4 to determine receptor occupancy. During each run, a 1%increase from the
baseline value in each parameter was set to determine the resulting change in predicted Rs and
sensitivity coefficients for each parameter were then calculated using the equation below:

( A  B)
Sensitivit y Coefficien t 

(C  D)

B

Equation 2.14

D
Where A and B are the endpoint parameter (in this case, Rs) with 1% increased in a parameter
value or with the original parameter value, respectively. C equals the parameter value increased
1% from original value, and D equals the original parameter value.
The most sensitive parameters were found to be rates for exocytosis and endocytosis, kex
and kin. It is not surprising that parameters accounting for binding to scaffolding proteins did not
influence total surface receptor levels highly. The individual numbers of free and bound
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receptors within the synaptic region (Rf and Rb) would be more sensitive to these parameters. It
should be noted that a limitation in this analysis is the fact that basal parameters are established
by SS analysis, based upon receptor densities found in the literature. Definitive receptor densities
were not available, especially for the extrasysnaptic and synaptic regions. If a higher degree of
receptor densities were assumed to be bound (movement restricted), then Kb and Ka would have a
greater influence.
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KB
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-0.002
-0.003

-0.004

Figure 2-9. Sensitivity coefficients for Each Parameter

Conclusions
A simple mathematical model of receptor trafficking between the postsynaptic and the
other regions of a dendritic spine was developed that provides a general theoretical framework for
investigating the role of trafficking in the expression of BZ-sensitive GABAA receptors. The
model was constructed similar to a single cell, with mainly first order rates to describe the
receptors’ kinetics. Steady state analysis was conducted, using estimated receptor densities from
the literature, to derive the proportional relationships between rate constants. The rate constants
were then specifically fitted against time course data from studies on GABAA receptor
movement. Differences found between the rate ratios developed from SS analysis and those
derived via optimization to in vitro data were slight. Sources of these differences are likely to
arise from differences in labeling techniques, differences between neuronal and recombinant cell
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types and/or the effects of different labels upon receptors’ configuration, movement, and
resistance to proteolysis within the lysosome and sensitivity to changes in pH.
For example, the endocytosis and exocytosis rates, kin and kex, established from SS analysis
describe relatively well the receptor internalization data seen in neuronal culture by Joshi and
Kapur (2009), but the rate of exocytosis observed in HEK cells is nearly double the neuronal
value (kex = 7.0 vs. 3.0). The difference may well be due to the fact that dense synaptic clustering
is lacking in non-neuronal cultures (Caruncho et al., 1993). In addition, surface receptor densities
are much lower in recombinant cell lines. Bradley et al. (2008) measured wild-type GABAA
receptors expressed in HEK293 cells, using a recombinant N-terminal FLAG epitope-tagged
α1β2 construct. The receptor’s cell surface expression averaged 44 ± 8% of the total cell
expression, nearly half of that measured in neuronal cultures by Czajkowski and Farb, 1989 (80%
of total receptor expression). Therefore, although constitutive endocytosis is similar between the
two cell types, the recombinant cell line may display a greater rate of exocytosis in an attempt to
maintain stable surface levels.
It is also important to keep in mind that GABAA receptor trafficking involves multiple
proteins such as clathrin, adaptor protein 2 (AP2) complex, dynamin, GABAA receptor associated
protein (GABARAP), Huntington-associated protein 1 (HAP1), protein linking integrinassociated protein to cytoskeleton-1 (PLIC1), and gephyrin (Kittler et al., 2000; Kittler et al.,
2005; Kanematsu et al., 2006) (Figure 1-3). Therefore, each rate constant represents a composite
of multiple processes, optimized to produce results consistent with the known experimental data
used in this analysis. Yet, the consistency in measured rates observed across a number of
different in vitro SE models and in animal models instills confidence in the model’s final
parameters.
Together, the trafficking model and the studies used to parameterized the receptor
trafficking model demonstrate that the surface stability of GABAA receptors can be rapidly and
specifically regulated, enabling neurons to modulate cell surface receptor number upon the
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appropriate cues, such as activity. The kinetics of the model depends upon various composite
trafficking parameters that could be targets of second messengers pathways activated during
seizures. The model was used to explore the consequence of targeting different parameters to see
how these parameter changes can reproduce a wide range of experimental data. To simulate SE
conditions, increases in the rates of endocytosis, kin, and lateral movement from synaptic to
extrasynaptic membrane regions, kc, appeared sufficient to describe the data. Obviously, that
does not rule out the possibility that additional parameters are altered significantly enough to
impact surface expression. However, for simplicity, the addition of unmeasured parameters was
limited to as few as necessary to describe the measured data. In the next chapter, the
development and validation of a diazepam PBPK model is discussed. The diazepam model is
then linked (in Chapter 4) with the receptor trafficking model described here to predict
pharmacoresistance.
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Chapter 3. Diazepam PBPK Model Development
The purposes of developing a PBPK model are 1) to demonstrate a means of
extrapolating animal studies to humans and 2) to predict the changing concentration of the
anticonvulsant and its major active metabolite in the “biophase”, so that it can be linked with the
dynamics of surface GABAA receptor expression during SE for predicting the time-dependant
dose response. Biophase refers to the target tissue where the drug exerts its pharmacological
effect. In this case, biophase refers to the brain. Diazepam was chosen as a suitable candidate for
illustrating this modeling approach as it is typically the first anticonvulsant used to treat SE and it
remains the conventional antidote to NA-induced seizures. In addition, considerable kinetic and
dose response data on this compound exist across species (including humans), doses and dose
routes, allowing for validation of model parameters and predictions. This model simulates the
anticonvulsant concentration in the brains of rats and humans from various dose routes, including
intramuscular (im) injections. This is important because kinetics resulting from im administration
are known to be highly variable in comparison to other dose routes, and im is the dose route of the
diazepam auto-injector (CANA), used by the military for NA-induced seizures. Lastly, because
PBPK models can be used to predict in vivo doses that result in brain concentrations that are
comparable to levels used in published in vitro studies on diazepam's effect on GABAA receptors,
the model assures equivalent dosimetry when applying in vitro results to predict in vivo effects.
Physiologically-based PK models have been developed previously that describe the absorption
and distribution of diazepam in the tissues of both rats and humans (Igari et al., 1983;
Gueorguieva et al., 2004). However, these models did not account for diazepam's major active
metabolite, desmethyldiazepam (DMD), which extends its half-life to up to 100 h, adding greater
nonlinearity to the drug's effects. In addition, these models had not been linked with a cellular
PD model accounting for the desensitization of BZ-sensitive GABAA receptors occurring during
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SE. Therefore, the current model takes previous work further to explore not only the impact of
the drug’s pharmacokinetics, but also the impact of the changing expression of the target receptor,
upon the drug’s pharmacodynamic profile.

PBPK Model Structure
The current PBPK model describes the distribution of diazepam and its major metabolite,
DMD (Figure 3-1). The model structure for diazepam includes distinct compartments for the
liver, brain, fat and kidney. The remaining tissues are lumped under richly and slowly perfused
tissues. From the liver compartment, the model links to a separate compartmental model for
diazepam’s major metabolic product (DMD). In selecting the compartments an attempt was
made to choose compartments most relevant to diazepam’s distribution and effect, while keeping
the model as simple as possible. For example, the liver and brain are important sites of
metabolism and pharmacological activity, respectively. Given diazepam’s high lipid solubility,
the drug quickly enters the brain and is redistributed to peripheral compartments and readily taken
up into fat. Therefore, fat has a major impact on the drug’s distribution.
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Figure 3-1. PBPK model structure for diazepam (DZ) and its major metabolite,
desmethyldiazepam (DMD).

Metabolism of diazepam occurs mainly in the liver by the cytochrome P450 (CYP)
enzyme system. Most of diazepam undergoes oxidative metabolism by desmethylation (via
enzymes CYP 2C9, 2C19, 2B6, 3A4, and 3A5) and hydroxylation (CYP 3A4 and 2C19) (Figure
3-2). The metabolites formed further undergo conjugation through glucuronidation in liver
microsomes. Glucuronides are secreted in bile and eliminated in urine. Hence, the drug
undergoes multiple phases of transformation, making the drug more polar and easier to excrete.
Diazepam has three pharmacologically active metabolites, which bind to the same
“benzodiazepine” site on the GABAA receptor with similar affinities (Arendt et al. 1987). Its
major active metabolite in humans is desmethyldiazepam (DMD) (also known as nordazepam or
nordiazepam). While diazepam has biphasic half-life, with a quick distribution half-life of 2-15
min, and a long terminal half-life of about 1-2 d; DMD’s long half-life is approximately 2-7 d
(Riss et al., 2008). Minor active metabolites include temazepam (TZ) and oxazepam (OX).
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These metabolites are readily conjugated with glucuronide, and are rapidly excreted by humans,
primarily in the urine. Less than 1% of the parent compound is excreted unchanged or as DMD
(Riss et al., 2008). Therefore, in congruence with the purpose of creating a model for human
extrapolations, only the major metabolite is modeled. However, the model still takes into account
the depletion of parent compound, resulting from the formation of the other metabolites, mainly
TZ. For simplification, compartments for tracking DMD include only the brain, liver and plasma,
while the rest of the body is lumped (Figure 3-1). Because DMD is not readily excreted, the
depletion of DMD is modeled as a metabolic loss to OX formation.

hydroxylation

demethylation

Vmax2
Km2

Vmax1
Km1

Vmax3
Km3
hydroxylation

demethylation

Desmethyldiazepam
glucaronic acid
conjugate

glucaronic acid
conjugate

Figure 3-2. Major and minor metabolites of diazepam

The PBPK model is a mix of algebraic and ODEs. The latter are mass balance equations,
which describe the rate of change of a chemical within a model compartment. Taken together,
the mass balance equations for all compartments describe how the chemical distributes within the
body. The amount of a chemical within a single tissue compartment at any time should equal the
amount of that chemical entering the compartment in the arterial blood stream, minus the amount
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leaving the compartment in venous blood stream, plus the amount taken up within the
compartment, minus any amount excreted (or metabolized).
Below is a mass balance equation for a compartment without metabolism or excretion
and whose concentration is limited by arterial blood concentration and blood flow.
Equation (3.1)
Where VT represents the tissue volume, QT is tissue blood flow and the subscript, T, represents the
particular tissue. CA is arterial concentration and CT and PT are the concentration in tissue and
the tissue/blood partition coefficient, respectively. These compartments are called “flow limited”
and include the liver, kidney, muscle, and richly and slowly perfused compartments. However, as
described later, the amount in the liver compartment is also impacted by metabolism and
elimination.
The rate of change in the amount of chemical in compartments in which the concentration is
limited by diffusion, such as brain and fat, is described as being proportional to the cell
membrane permeability coefficient (PAT) for tissue (T), as shown in the equations 3.2 and 3.3.
Tissue uptake is said to be diffusion-limited when PAT < QT.
Equation (3.2)
Where: VTB is the volume of blood in the tissue, CVT is the concentration in the tissue’s blood
(capillary bed) and PAT (cell membrane permeability coefficient, L/h). The tissue concentration
(CT) can then be derived from the tissue blood concentration (CVT) as follows:
Equation (3.3)
To model DMD formation and clearance, the diazepam model branches off from the liver
compartment, as Vmax1, into a separate compartmental model, in which this major metabolite is
tracked in liver, brain and plasma (Figures 3-1 and 3-2) and the other metabolites are lumped as
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Vmax2 below. Hence, the rate of change in DZ concentration within the liver is described using
flow limitation and saturable metabolism (forming DMD and TZ):
Equation (3.4)
Where: CVL is the concentration of diazepam in the liver capillary bed (CVL = CL/PL), Vmax1 and
Km1 are the Michaelis Menten (M-M) maximum velocity and affinity constants for the conversion
of diazepam to DMD and Vmax2 and Km2 are the M-M constants for the conversion of diazepam to
TZ.
Within the DMD model, the rate of change of DMD in the liver is described similarly:
Equation (3.5)
Where: CL DMD is the concentration of DMD in the liver, CL DMD is the concentration of DMD in
liver capillary bed, and Vmax3 and Km3 are the M-M constant for the conversion of DMD to OX,
which is glucoronidated and eliminated in feces. Therefore, although the minor metabolites, TZ
and OX, are not modeled and tracked specifically, their clearance from the system is accounted
for.
Routes of exposures modeled include: iv, ip and im injections. Intravenous infusion was
modeled as a zero-order rate into venous blood, based upon the length of the injection time.
Intramuscular and im injections were models as first-order absorption from a small muscle or
peritoneal compartment into the entire muscle or liver, respectively.

Allometric Scaling
To account for variation associated with size, all rate constants are scaled by BW0.74 as
shown below:
QC = QCC× BW0.75

Equation (3.6)

PAF = PAFC × BW0.75

Equation (3.7)

Vmax= VmaxC×BW0.75

Equation (3.8)
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Model Parameterization
The rate of entry of any drug into a tissue depends on blood flow to the tissue, the tissue
volume, and partition characteristics between blood and tissue. Equilibrium in distribution (when
entry and exit rates are the same) between blood and tissue is reached more rapidly in richly
perfused areas (e.g., kidney and brain), unless diffusion across cell membranes is the rate-limiting
step. After equilibrium, drug concentrations in tissues and in extracellular fluids are reflected by
the plasma concentration. Metabolism and excretion also occur simultaneously with distribution,
making the process dynamic and complex.
Parameters used to describe these processes within the PBPK model are physiologically
and chemical specific. Physiological parameters, describing blood flows and tissue volumes, for
rat and man were obtained from experimentally measured data compiled by Brown et al., 1997
(see Table 3-1). Chemical-specific parameters include tissue:plasma partition coefficients (PT)s,
extent of plasma binding and metabolic and clearance rates. Tissue:plasma partition coefficients
are critical parameters in PBPK modeling as they represent steady state chemical distribution and
generally are fairly consistent across species. The PTCs used here (Table 3-2) for diazepam and
DMD represent whole tissue to plasma (unbound) concentration ratios measured in vivo at 480
min post iv injection of 1.2 mg/kg DZ in rats (Igari et al., 1983), when a pseudo equilibrium is
achieved. The unbound fraction in plasma was determined by equilibrium dialysis. The
partitioning of diazepam between plasma and erythrocytes in rat was also measured, resulting in a
blood to plasma ratio of 1.03 ± 0.007 (Igari et al., 1983).
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Table 3-1 Physiological parameter values
Parameter
Name
Rat
Human
(Constants)
Body weight (kg)
0.3
70.0
BW
Cardiac output (blood flow) (L/hr-kg)
15
16.5
QCC
Tissue Blood Flow Constants [fraction of QC]
Liver
0.18
0.23
QLC
Fat
0.09
0.05
QFC
Brain
0.03
0.11
QBrC
Kidney
0.14
0.14
QKidC
Muscle
0.28
0.19
QMuC
Richly perfused
0.12
0.11
QRC
Slowly perfused
0.16
0.17
QSC
Peripheral body = 1.0-QL-QBr
0.79
0.66
QBodC
Tissue Volume Constant [fractions of BW]
Liver
0.034
0.026
VLC
Fat
0.07
0.21
VFC
Brain
0.0057
0.02
VBrC
Kidney
0.007
0.007
VKidC
Muscle
0.40
0.40
VMuC
Venous blood
0.054
0.056
VVenC
Arterial blood
0.027
0.024
VArtC
Richly perfused
0.21
0.16
VRC
Slowly perfused
0.27
0.18
VS C
Peripheral Body VBOD = 1.0-VL-VBr
0.96
0.95
VBodC
Tissue blood volume constants [fractions of tissue volumes]
Blood fraction of liver
0.21
0.11
VLBC
Blood fraction of fat
0.02
0.02
VFBC
Blood fraction of muscle
0.04
0.01
VMuBC
Blood fraction of brain
0.03
0.04
VBrBC
Source: All volumes and flows taken from Brown et al., 1997.
Blood flow constants are multiplied by QC to yield tissue blood flows (L/hr-kg) used in
model.
Tissue volume constants are multiplied by BW to yield tissue volumes (L) used in model.
Tissue blood volume constants are multipled by the volume of the corresponding tissue to
yield the blood volume of that tissue (L).
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Table 3-2. Chemical Specific Tissue:Plasma (Unbound) Partition Coefficients

-

Tissue:PlasmaUnbound 1 for DZ (unitless)

(PT)s

Brain (PBr)
Kidney (PKid)
Liver (PL)
Muscle (PMu)
Fat (PF)
Slowly diffused (i.e., muscle)(PS)
Richly diffused (i.e., kidney) (PR)

7.03
15.9
33.7
9.9
88.9
9.44
15.9

Tissue:PlasmaUnbound for DMD (unitless)
Brain (PBrDMD)1,2
Liver (PLDMD)2
Remaining Body (PBodDMD)2
1
Sources: (Igari et al., 1982; 1983)
2
Optimized to experimental data

8.0
30
60

Plasma Protein Binding and its impact on tissue:plasma partition coefficients.
The amount of diazepam distributed into tissues depends on the extent of binding in the
blood and tissues. In the bloodstream, diazepam is transported partly in solution as free
(unbound) drug and partly reversibly bound to blood components (e.g., plasma proteins, red
blood cells). Only unbound diazepam is available for passive diffusion into interstitial fluids,
tissue cells as well as to extracellular regions of target sites where the pharmacologic effects of
the drug occur. Therefore, the free fraction (FF) of the drug concentration in systemic circulation
typically determines drug concentration at the active site and thus efficacy and this value differs
across species. Because total plasma concentrations are being simulated as partitioning into the
tissues and measured whole plasma concentrations are being used for validation, the PTs, which
represent tissue:plasma (unbound), must be adjusted to account for the bound fraction which
cannot partition into the tissue. To account for this the PTs are multiplied by the FF to yield the
species-specific tissue:plasma (total) ratios, as shown:
Equation (3.10)
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Diazepam and DMD are both extensively bound to plasma proteins. Moschitto and
Greenblatt (1983) quantified the binding extent of normal human plasma to ten different BZs and
found that plasma binding was concentration-independent and therefore should not complicate
the interpretation of pharmacokinetic studies. The average FF for DZ and DMD were 0.016 and
0.035, respectively. These values did not vary significantly across a range of concentrations from
10.0 to 10,000 ng/ml. With the exception of some cases of massive overdose, plasma levels
encountered during therapeutic use do not exceed this upper limit (Greenblatt et al., 1978). In
humans, following single iv doses from 5 to 10 mg, the average FF of DZ was found to be 0.015
± 0.002 % (Greenblatt and Divoll, 1983). Klotz et al., 1976 reported an FF of approximately
0.032 ± 0.008 % in humans. The high level of plasma binding for these compounds is supported
by studies in other species. Wala and Sloan (1995) measured the FF in dog plasma. In dog
plasma containing 0.5 and 20.0 μg/ml of diazepam or DMD, the FF was 0.038 ± 0.003 and 0.077
± 0.018 for diazepam, and 0.034 ± 0.004 and 0.048 ± 0.006 for DMD, respectively. Plasma
binding occurs to a lesser extent in the rat. Binding studies in rat plasma, indicate FF of
diazepam and DMD to be 0.137 ± 0.011 and 0.095 ± 0.01 (Klotz et al., 1976). Here, to simulate
the unbound concentration of diazepam and DMD in plasma, FFs of 0.14 and 0.095 for the rat
and 0.03 and 0.04 for humans, are used respectively, resulting in the adjusted species-specific PTs
shown in Table 3-3.
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Table 3-3. Species-Specific Tissue:Plasma (whole) Partitioning and Permeability
Coefficients
Tissue:PlasmaUnbound for DZ1 (unitless)

Rat

Human

Brain (PBr)
Kidney (PKid)
Liver (PL)
Muscle (PMu)
Fat (PF)
Slowly diffused (i.e., muscle)(PS)
Richly diffused (i.e., kidney) (PR)

0.98
2.2
4.7
1.4
12.0
1.3
2.2

0.21
0.48
1.0
0.3
2.7
0.28
0.48

Tissue:PlasmaUnbound for DMD1, 2 (unitless)
Brain (PBrDMD)
Liver (PLDMD)
Remaining Body (PBodDMD)

0.76
2.8
5.7

0.3
1.2
2.4

Cell Membrane Permeability Coefficients (PA) (mg/L/h)2
Brain (PABr-DZ)
0.9
1.0
Fat (PAF-DZ)
1.0
1.0
Brain (PABr-DM)
1.0
0.05
Body (PABodDMD)
5.0
5.0
1
Notes: Tissue:Plasma (whole) values derived from values in Table 3-2 multiplied by the
FF in rat and human plasma. The FF for diazepam and DMD were 0.14 and 0.095 for
the rat and 0.03 and 0.04 for humans, respectively.
2
Values optimized to experimental data.

Metabolic Parameters and Tissue Permeabilities of Diazepam
Michaelis Menten (M-M) constants (Km) from various studies in multiple species were
evaluated and compared while simulating the metabolism and clearance of diazepam during its
conversion to DMD and further metabolic clearance of DMD. Approximate Km values collected
from in vitro rat liver slice studies (Saito et al., 2004a, b) and human liver microsomes
(Andersson et al.,1994) were used. However the permeability coefficients (PAs) and maximum
velocities (Vmax’s) were visually optimized to the kinetic data from Igari (1983) for the rat, while
all other parameters (e.g., partition coefficients and physiological parameters) were set to those in
Tables 3-1 and 3-3. With compartments described by diffusion limitation, such as fat, the PAs
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were optimized to the early uptake portion of the corresponding tissue data, while metabolic Vmaxs
were optimized to the later clearance portion of the curve of liver and plasma data. Similarly, the
Vmax values used for human were optimized to individual human kinetic studies, which are
described in the results (see Table 3-5). These values were then averaged and the final metabolic
constants are shown in Table 3-4.

Table 3-4 Metabolic Parameters
Vmax (mg/h/kg)
Rat
Source
Human
1
Vmax1 N-desmethylation
15.0
Optimized
3.6
Vmax2 3-hydroxylation
10.0
Optimized1
0.40
Vmax3 hydroxylation
3.0
Optimized1
0.36
Km (mg/L)
Km1 N-desmethylation,
24.9
Saito et al., 2004a
52.4
Km2 3-hydroxylation,
25.0
Saito et al., 2004a
53.5
Km3 hydroxylation ,
25.03 Saito et al., 2004a1
50.03
1
optimized using data from Igari et al., 1983 or from human studies
2
see Table 3-5.
3
Km3 and Km2 values for both hydroxylation steps are assumed similar.

Source
Optimized2
Optimized2
Optimized2
Andersson et al., 1994
Andersson et al., 1994
Andersson et al., 19941

Experimental data
As described above, a final step in parameterization involved simulating experimental
data from an extensive kinetic study by Igari et al., (1982). The resulting chemical specific
parameters, listed in Tables 3-5, were then tested via simulation of other published kinetic data.
The experimental data from the other studies then served as validation of the model, with
exception of the human studies, which also served to optimize Vmax values for the metabolism of
diazepam. The data presented in this chapter were digitized, from the following published PK
studies in rats and humans.

Rat Data:


Igari et al. (1982): Male Wistar rats, weighing 250-270g were administered 14C-

diazepam diluted with unlabeled diazepam in polyethylene glycol (1.2 mg/kg) by iv injection.
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At various times after iv injection, tissues were collected and analyzed for diazepam, DMD,
OX and TZ, N = 3-5 rats/time-point. The diazepam and DMD data from this study were used
in the development and optimization of model parameters.


Gueorguieva et al. (2004): Tissue and arterial blood were collected following an iv

infusion over 5 min, of 1 mg diazepam in each of 24 male Sprague-Dawley rats (weighing
approximately 250 g each, 4 mg/kg). Four of these animals were then sacrificed at each of
the following time points: 7, 10, 20, 35, 95 and 245 min when various tissues were dissected
out for analysis. Plasma samples were taken from the carotid artery at those same times as
well as at 2 and 5 min. Samples were quantified for diazepam by a specific and appropriately
validated Liquid chromatography–tandem Mass Spectrometry) (LC–MS) method.


Friedman et al. (1986): Male Charles River CD-1 rats were each given a single im

injection of 5 mg/kg diazepam. Four rats were sacrificed at 5, 15, 30 min, 1h, 1.5, 2,3,4,5
and 6h. Brain and plasma samples were collected and analyzed for diazepam and DMD by
electron-capture gas chromatography.

Human data:


Mould et al. (1995). A healthy male volunteer received 0.1 and 0.2 mg/kg diazepam on

separate occasions. Plasma was collected over three hours and analyzed for diazepam.


Greenblatt and Divoll (1983). Healthy volunteers, ages 21-78 received a single iv dose

of diazepam. Data illustrated was for one male subject given 7.5 mg diazepam (0.1 mg/kg).
Following administration, multiple venous blood samples were drawn over the next 5 - 10 d.


Ochs et al. (1985): Healthy volunteers received 5 mg diazepam via rapid iv injection.

Blood was collected over 168 h. The unbound plasma fraction was determined using
equilibrium dialysis to be 1.42%.
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Klotz (1976): Ten healthy male volunteers, ages 23-35 y, were administered diazepam

(0.1mg/kg) iv over 2 min. Data was illustrated for one subject.


Jack and Colburn (1983): Four healthy male volunteers, ages 25-43, each received an iv

injection of 10 mg diazepam. Blood was collected at 1, 2.5, 5, 10, 20, 30, and 45 min and at
1, 1.5, 2, 3, 4, 6, 12, 24, 30 and 48 h following administration. Blood samples were analyzed
for diazepam and DMD by electron-capture GLC.


Lehmann and Wannarka (2008): Ten mg diazepam was administered by autoinjector in

24 healthy male subjects (mean age = 25.7 ± 2.4 y and BW = 74.5 ± 2.4 kg). All injections
were delivered into the midanterolateral thigh, two inches lateral from the midpoint of the
midline between the anterior superior iliac spine and the end of the knee bent. Blood samples
were collected predose and at several post dose time points to 240 hours and analyzed using
gas chromatography with an electron capture detector for plasma diazepam and DMD. The
ranges of concentrations for the assay were 5 to 400 ng/mL for diazepam, and 5 to 120 ng/mL
for DMD.

Results
Model simulations of diazepam kinetics in the rat, using the parameters listed in Tables
2-4, are illustrated in Figures 3-3 – 3-5. As previously mentioned the Igari data shown in Figure
3-3 was used to optimize PA’s and Vmax’s. The simulations shown in Figures 3-4 and 3-5
demonstrate validation of the final rat parameters. Using the final set of parameters, the model is
in accord with measured experimental data from a variety of kinetic studies in rats. The
reasonable agreement between simulations of brain concentrations and measured experimental
data also provides confidence in the use of the model for predicting receptor occupancy in the
next chapter. Intraperitoneal injections were simulated in Figure 3-5. The injection and diffusion
into systemic circulation were described using a first order rate (Kip) of 3h-1 from an
“intraperitoneal compartment” into the liver compartment. Here the model simulation exceeds
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early plasma time-points, but simulates brain concentrations well. However, plasma
concentrations, resulting from ip injections, are typically more variable than iv injections. This is
because with ip, the primary route of absorption is into mesenteric vessels, which drain into the
portal vein and pass through the liver. Therefore, the drug may undergo hepatic metabolism
before entering systemic circulation. This appears to be demonstrated by the measured data in
Figure 3-5, which suggest that diazepam and DMD were metabolized to a greater extent before
entering the blood stream. In some incidences of ip injections, the needle may be delivered

Concentration (mg/kg)

directly into a blood vessel within that region, but that does not appear to be demonstrated here.

1

2

1

Plasma

0.1

Kidney

0.1

1
0.01

Fat

0.01

1E-3

1E-3
0

2

4

6

8

0

2

Hours

4

6

8

0

2

Hours

4

6

8

Hours

Concentration (mg/kg)

1
1

1
0.1

Brain
0.1

0.1

0.01

0.01

Muscle

Liver
0.01

1E-3

1E-3

1E-3
0

2

4

Hours

6

8

0

2

4

6

Hours

8

0

2

4

6

8

Hours (h)
41

Figure 3-3. Predicted (solid lines) vs. observed mean diazepam (black squares) and DMD (red
triangles) concentrations in plasma, liver and brain, and DZ alone in kidney, muscle and fat in
male Wistar rats following an iv injection of 14C-diazepam diluted with unlabeled diazepam (1.2
mg/kg) N = 3-5 rats/time point ). Data from Igari et al. (1982), SDs were not provided.
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Figure 3-4. Predicted (solid line) vs. observed (squares) diazepam concentrations in plasma and
other tissues in Sprague-Dawley rats following iv infusion of 1 mg diazepam (4 mg/kg) over 5
min, N = 4 rats/timepoint. Data from Gueorguieva et al. (2004).
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Figure 3-5. Predicted (solid line) vs. observed diazepam (black squares) and DMD (red
triangles) concentrations in plasma and brains of Male Charles River CD-1 rats given an ip
injection of 5 mg/kg diazepam (n=3-4/time-point. Data taken from Friedman et al. (1986).
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Simulations of human studies are shown in Figures 3-6 and 3-7. Diazepam kinetics differ
between rats and humans. Equal doses (normalized to BW) result in higher concentrations in
humans. Given the higher average body fat content of humans vs. rats (21% vs. 9%), one may
initially assume that humans would have a greater capacity to store lipophilic compounds,
resulting in lower plasma levels especially initially. However, because fat is poorly perfused,
equilibration time is long. The source for the higher plasma levels noted in humans can be
attributed to lower capacities of metabolic clearance in the human, as well as differences in
plasma binding kinetics.
Individual human plasma concentrations could not be described using a single set of Vmax
values. Therefore, Vmax values were optimized to each study shown in Figure 3-6 and 3-7 to
derive average Vmax values (see Table 3-4). The appearance of DMD in plasma was used to
derive Vmax1, representing the desmethylation of diazepam, while optimizing the remaining
clearance of diazepam was used to establish Vmax2, the oxidation of diazepam.
Desmethyldiazepam is, to a major extent, metabolized by 3-hydroxylation to oxazepam.
Therefore, the total clearance of DMD is possibly a reliable estimate of the rate of 3hydroxylation (Vmax3) of this compound. Bertilsson et al. (1989) measured an average of 62% of
DZ biotransformed to DMD in humans, and this was consistent with our simulations. Their
fraction is consistent with other studies, such as a PK analysis of DMD plasma levels by Jack and
Colburn (1983), which predicted 50% of DZ is metabolized to DMD.
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Figure 3-6. Predicted (lines) vs. observed diazepam (black squares) and DMD (red triangles)
concentrations in plasma of a healthy male administered iv 0.1 and 0.2 mg/kg DZ on separate
occasions. Data taken from Mould et al. (1995).
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Figure 3-7. Predicted (solid lines) vs. observed diazepam (black squares) and DMD (red
triangles) concentrations in plasma of individual healthy males, administered the following doses
of diazepam iv: A) 0.07 mg/kg (Ochs et al., 1985), B) 0.1 mg/kg (Greenblatt and Divoll, 1983),C
0.1 mg/kg (Klotz et al., 1976), and D) 0.14 mg/kg (Jack and Colburn, 1983). In each study, data
for only one individual was illustrated.
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Figure 3-8. Predicted (solid lines) vs. observed concentrations (Mean + SD) of diazepam
(squares) and DMD (triangles) plasma levels following one 10-mg diazepam im autoinjector
administered into the midanterolateral thigh. A) simulations and data for the first 1.4 h, B) same
simulations and data extending out 240 h. Data taken from Lehmann and Wannarka (2008).
Table 3-5. Human Vmax Values Optimized to Experimental Data
Data Source

Vmax1
(mg/kg/h)
5.0
4.0
3.8
4.0
2.0
3.8 ±1.09

Jack and Colburn, 1983
Ochs et al., 1985
Klotz et al., 1976
Greenblatt and Divoll, 1983
Lehmann and Wannarka, 2008
Average ± SD

Vmax2
(mg/kg/h)
0.1
0.1
0.1
0.1
0.5
0.18 ±0.18

Vmax3
(mg/kg/h)
0.6
0.2
0.5
0.2
0.09
0.31 ±0.22

Using the human values from Tables 3-1, and 3-3, which includes the average Vmax values
complied in Table 3-5, plasma and tissue concentrations in man are predicted and shown in
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Figure 3-9.
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Figure 3-9. Model simulations (lines) of diazepam concentrations in fat, plasma, liver, brain and
muscle in humans following 1.2 mg/kg iv.

Conclusions
A PBPK model was developed, which predicts diazepam concentrations in multiple
tissues, including the drug’s target tissue, the brain. Diazepam was chosen as a suitable
anticonvulsant to model as it remains the primary therapeutic used to treat status epilepticus.
Some basic assumptions used in the model include: 1) all tissue densities were equivalent with
water (i.e., 1.0 g/ml), 2) instant equilibrium occurs between tissue and blood in flow-limited
compartments, 3) 100% of the parent compound, diazepam, is eliminated via metabolism in the
liver, 4) tissue concentrations, (CT)s, include amounts and volumes of capillary beds, extracellular
fluid and possible deep pools, and 5) tissue uptake is largely influenced by the plasma FF.
Interspecies and individual differences, particularly in plasma binding and metabolism did not
allow for direct extrapolation of the model from rat to human by simply applying human-specific
physiological parameters (i.e., blood flows and tissue volumes). This is typical of highly
lipophilic compounds, which tend to bind more readily to proteins. The unbound fraction of
diazepam in plasma is much lower in humans than in rats (i.e., 0.016-0.03 vs. 0.14). In addition,
diazepam metabolism differs between species and within species. Individual metabolism rates
are influenced by genetic factors, coexisting disorders (particularly chronic liver disorders and
advanced coronary failure), and drug interactions (especially those involving induction or
inhibition of liver enzymes). These phenotypic differences demonstrate the utility of kinetic
investigations and in vitro studies on drug metabolism at clinically relevant substrate
concentrations, when evaluating novel therapeutics. Considering the wide physiological
variations in the drug’s metabolism, model simulations matched experimental data well.
The major metabolite of diazepam, DMD, was modeled, as it has been reported to extend
diazepam’s half-life and have a major impact upon its pharmacodynamics. However, in both the
rat and human, DMD does not exceed diazepam concentrations in brain or plasma, respectively,
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at earlier time points, which are most important in regards to acute dosing following SE onset.
This is in contrast to concentration profiles of diazepam and DMD in mouse and guinea pig
brains, in which DMD levels exceed diazepam following a single iv injection (Marcucci et al.,
1971). In rats and humans, however, DMD levels may exceed those of diazepam following
repeated dosing, as large amounts would be stored in fat and slowly released (Marcucci et al.,
1979). Hence, the capacity to simulate metabolite concentrations becomes more importance
when extrapolating acute diazepam data from mice, guinea pigs or other species which
metabolize the compounds more extensively; or when modeling diazepam exposures in any
species involving multiple doses over a prolonged period
It is well-known that individuals metabolize diazepam differently. Reasons for these
differences may be attributed to genetic factors, age or even normal variations in physiology
across the general population. Because metabolism is the primary elimination route for
diazepam, the metabolic constants used are sensitive parameters. Further improved upon via
sensitivity analysis to identify which parameters have the greatest impact upon kinetics. Then,
based upon a priori information regarding the sensitive parameters, those with the most
uncertainty can be identified for further study. Variability analysis would also enhance the
model’s reliability by predicting a range of physiological reasonable concentrations that reflects
the population diversity.
Lastly, plasma, brain and other tissues concentrations predicted from the proposed PBPK
model were validated against data from studies, in which diazepam was administered alone in
normal animals. When diazepam is administered following the onset of seizures, higher brain
concentrations may be expected due to seizure disruption of the blood brain barrier (BBB) and
subsequent increased permeability. However, Capacio et al (2001) has compared diazepam
concentrations in plasma and particular brain regions [cerebellum, cortex, brain stem and cerebral
spinal fluid (CSF)] in rats that had undergone seizures with rats who had not, and found
significantly higher levels in the plasma of animals that seized, but no significant difference in
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concentrations of the selected brain regions or CSF. Given the high lipophilicity of diazepam
(log kow ≈ 2.8), the BBB may not be much of a hindrance to its uptake. Therefore, using a model
in which brain permeability was parameterized using data from animals dosed with diazepam
alone, to validate brain concentrations achieved during SE appears appropriate.
In the following chapter, the PBPK model is linked with the GABAA receptor trafficking model,
developed in Chapter 2, and used to predict receptor occupancy, which is then correlated with
efficacy and pharmacoresistance with increasing time from seizure onset.
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Chapter 4. Linking Diazepam PBPK with PD, based upon GABAA Receptor Trafficking

In this chapter, the cellular model of GABAA receptor trafficking (Chapter 2) and the
PBPK model for diazepam (from Chapter 3) are linked to characterize the degree of receptor
occupancy required to terminate seizures. The occupancy of GABAA receptors by BZs has been
found to be a good correlate, or dose metric for a number of different BZ effects (Greenblatt and
Sethy, 1990; Ito et al., 1993; Facklam et al., 1992). Theoretically, by accounting for the
concentration of diazepam reaching the GABAA receptor (the “biophase” concentration) as well
as the rapidly diminishing levels of that receptor during SE, we may investigate whether the level
of receptor occupancy remains a consistent dose metric for the anticonvulsant effect of diazepam
when given either before or after the onset of SE in vivo.

Predicting Receptor Occupancy by Diazepam Before and After Onset of SE

Experimental Data
To examine the impact that the rapidly changing GABAA receptor expression during SE,
plays in the pharmacoresistance to diazepam in vivo, we use the dose response data from two
studies, which evaluated the drug’s anticonvulsant efficacy when given either before (“seizure
prevention/survival”) or after induction of SE (“seizure termination/reversal”). Seizure
prevention/survival studies have limited applicability to modeling pharmacoresistance because
the anticonvulsant is delivered before seizure-induced changes in the receptor surface expression
occur. However, such studies do provide an estimate of receptor occupancy required for full
protection when an anticonvulsant is administered at time zero or slightly before seizure onset
(during normal conditions). Below is a brief description of both studies.
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Igari et al. (1985) measured time courses of anticonvulsant efficacy and receptor
occupancy in brain when seizures were induced at different times after iv administration of
diazepam. Rats were administered 1.2 mg/kg diazepam iv at time zero, then challenged with 100
mg/kg ip of pentylenetetrazol at 3, 10, 30, 60, 90, 120, 150, 180 and 240 min post diazepam
administration and monitored for behavioral seizures. Pentylenetetrazol is a GABAA antagonist,
used to induce seizures. In addition, rats which received only diazepam, were sacrificed at the
same time points of the pentylenetetrazol administrations in the other (seizure-induced) group of
rats. Whole brains (minus cerebellum, brain stem and olfactory bulbs) were harvested for ex vivo
determination of the apparent number of diazepam occupied receptors, using 3H-diazepam (2.7
nM) and unlabeled diazepam (3 μM) binding to the P2 synaptosomal fraction. Among the
pentylenetetrazol challenged animals, all vehicle pretreated rats exhibited all stages of seizures
(based on Bastian et al., 1959) followed by death. On the other hand only those that received the
pentylenetetrazol challenge three min post diazepam were fully protected. The anticonvulsant
efficacy decreased with time (as circulating diazepam diminished), with no protection seen 240
min post diazepam.
Kapur and Macdonald (1997) measured the anticonvulsant effect from various iv doses of
diazepam, administered either 10 or 45 minutes after the induction of SE by pilocarpine. Status
epilepticus was induced in rats by ip injection of lithium chloride at 3 mEq/kg followed by an ip
injection of pilocarpine at 50 mg/kg, 16-24 hr later. Three stages of behavioral seizures, as
classified by Racine et al. (1972), were induced in all rats within one to five minutes of the
pilocarpine injection. Diazepam was then administered at increasing doses either 10 or 45 min
post pilocarpine and the percent of rats that were seizure free within 5 min were counted, as
shown in Figure 4-1.
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Figure 4-1. Efficacy of Diazepam in controlling brief (10 min) or prolonged (45 min)
pilocarpine induced seizures in rats. Seizures were induced in 70–150 gm rats by ip injection of
LiCl at 3 mEq/kg followed 16–24 hr later by ip injection of pilocarpine at 50 mg/kg. Behavioral
seizures started within 1–5 min in all rats. Diazepam was administered ip 10 min (black squares,
n =14) or 45 min (red squares, n = 12) after pilocarpine injection. The percent of rats that were
seizure free within 5 min of diazepam are plotted against the log of the diazepam dose (Figure
recreated from Kapur and Macdonald, 1997).

Predicting Receptor Occupancy
Fractional receptor occupancy (FO) can be calculated as a function of the drug’s
concentration and affinity for a receptor as shown:
Equation (4.1)
where: CBr represents the unbound concentration of the drug reaching the receptor and Kd(in vivo) is
the equilibrium dissociation constant, or the brain concentration CBr required to occupy half of the
receptors (FO = 0.5).
It is believed that only free drug in the interstitial spaces of the brain is available to
interact with most CNS receptors (Watson et al., 2009). Therefore, in an attempt to better
correlate receptor occupancy with pharmacodynamics, it is essential to predict unbound brain
concentrations that are physiologically relevant. Thus equation 4.1 becomes:
Equation (4.2)
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As described in Chapter 3, the PBPK model predicts whole brain concentrations, which
were validated against measured data. Steady state concentrations of free (unbound) diazepam in
brain and blood have been measured using microdialysis probes in rats, receiving an acute steady
state infusion (Dubey et al., 1989) and in dogs, administered diazepam 3 times a day (every 8 h)
and stabilized at 27 mg/kg/d for 18 weeks (Wala et al., 1991). The ratio of free fractions
(unbound) in microdialysis perfusate of brain and plasma of rats was 0.95 ± 0. 17. In diazepam
dependent dogs, the free brain/plasma concentration ratio was 0.982 ± 0.039. These studies
suggest that the unbound fractions in the brain are close to the unbound fraction in plasma.
Therefore, considering the free drug hypothesis, it appears reasonable to consider the free drug
concentration in plasma (CVunbound) as a surrogate for (equal to) free brain concentration (CBr
unbound)

especially for lipophilic drugs like diazepam, which passively partition across the BBB.

Under this assumption, since PBr = CBr/CVunbound is the brain (total) to plasma (unbound)
concentration ratio , the unbound concentration in the brain, CBr (unbound) ,can be calculated as:
Equation (4.3)
Substituting for CBr from equation (4.3) into equation (4.2) (and multiplying top and bottom by
PBr) gives:
Equation (4.4)
So, comparing equation (4.1) and (4.4) gives:
Equation (4.5)

This approach was used by Igari et al., (1985) in their investigation into the relation
among diazepam time course and receptor occupancy, mentioned above. Therefore, the apparent
Kd(in vivo) (which was calculated to be 226 ng/ml, based on measured brain concentrations vs.
anticonvulsant effect), and the whole brain to plasma (unbound) ratio, PBr of 7.03, which was
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previously determined in a pharmacokinetic study by the same authors (see Table 3-2), an
apparent Kd (unbound) of 0.033 mg/L (

ng/ml) is derived.

However, this “unbound” in vivo dissociation constant value is still nearly 50 times
higher than dissociation constants measured in vitro for specific binding of diazepam to the P2
synaptosomal fraction of different brain regions, Kd (in vitro) , which range from 2.3 nM (6.56x10-4
mg/L) to 9.57 nM (2.73x10-3 mg/L)(Arendt et al. 1987; Braestrup and Squires., 1977; Igari et al.,
1985; Mohler and Okada, 1977; Nutt and Minchin, 1983, Wu and Phillis, 1986). The most
obvious explanation for the discrepancy between the Kd (in vitro) and the “effective half saturation
constant”, Kd (unbound), are the different conditions for assaying receptor function and binding
characteristics. The in vivo “unbound” value is derived from a functional study performed under
physiological conditions, whereas in vitro binding studies are performed under conditions
established artificially to obtain the P2 fraction for optimizing the ligand binding measurement.
The presence of proteins (in vivo) that bind to the receptor may be partially responsible. It has
been suggested that the high affinity seen in vitro reflects a desensitized state of the receptor
(Edgar and Schwartz, 1992). Because we cannot actually determine how much drug is reaching
the synaptic region in vivo, the Kd (unbound) is used to calculate receptor occupancy from the dose
response studies described above.
Igari et al. reported a very high correlation (r=0.977) between receptor occupancy and
anticonvulsant effect. Therefore, the magnitude of the physiological response (or seizure
termination) should be proportional to the amount of diazepam bound to the GABAA receptor
Because the surface expression of GABAA receptors is quickly diminishing with seizure duration,
we combine the decreasing number of receptors with the fractional occupancy of the remaining
receptors (equation 4.2), to determine the percent of original receptor occupancy of the original
receptor number (FOORN):
Equation (4.6)
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where Rst and Rs0 are the levels of surface GABAA receptors at time, t, and at time zero,
respectively. This equation asserts that as the number of original receptors declines, a higher
concentration of ligand is required to achieve the same occupancy. It is also assumed that the
legend’s on and off rates are fast enough so that the amounts of free ligand and ligand-specific
binding sites are in instant equilibrium.
Because the metabolite, DMD, is also centrally active and shares similar affinity for the
GABAA receptor, the model was written to include DMD’s possible contribution to receptor
occupancy. While levels of diazepam and DMD can be measured in the rat brain, it is not
possible to determine the relative contributions of diazepam and DMD to net receptor occupancy
based on the ex vivo techniques. Therefore comparison of net occupancy values (attributable to
diazepam plus DMD) with predicted brain concentrations requires normalization of DMD
concentration values (mg/L) based on the relative molecular weights of diazepam and DMD
(284.7 and 270.7, respectively) and relative in vitro benzodiazepine receptor dissociation
constants taken from the same study (9.57 and 5.58 nM, respectively) (Arendt et al. 1987) as
follows:
“

Z e uivalents

Equation (4.4)

where: CBr DMD is the brain concentration of DMD and PBrDMD represents the ratio of whole brain
DMD concentration to plasma (unbound) DMD concentration, which is approximately 8.0 (see
Table 3-3). The unbound “brain equivalents” are then accounted for by their addition to the
unbound brain concentrations of diazepam in Equation 4.3.

Results
Based on the approach described, time courses of free brain concentrations were
simulated from the doses used in the two studies described above and linked with the simulated
time-dependant changes in the GABAA receptor numbers during SE. In Igari et al.(1985) ex vivo
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measurements of receptor occupancy were performed at 5 time points following the
administration of 1.2 mg/kg diazepam. Figure 4-2 illustrates the model predictions of brain
concentration and receptor occupancy from that study, used here for model validation. It is
important to remember that in these simulations, diazepam was administered in the presence of
no seizures, therefore the basal or “original” number of receptors was available for occupancy.
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Figure 4-2. Model simulations of brain concentration and receptor occupancy time courses
following 1.2 mg/kg diazepam in rats. On left, lines (black and red) and symbols (squares and
triangles) indicate model simulations and measured diazepam and DMD concentrations,
respectively. The simulated brain concentrations are used to predict receptor occupancy (on
right shown as receptor occupancy(line) vs. ex vivo measurements(squares) (Igari et al., 1985)
(n=3 rats).

Igari reported that only those animals administered diazepam 3 min before the
pentylenetetrazol challenge remain 100% seizure free. Therefore, based upon the ex vivo
receptor measurement taken at 3 min (Figure 4-2 B), close to 37% receptor occupancy was
achieved, which resulted in complete prevention of behavioral seizures. At 10 min post
diazepam, the measured receptor occupancy was approximately 25% and animals had
experienced twitching. Therefore, the actual level of receptor occupancy required for complete
protection, when diazepam is given immediately before onset of seizures may actually be
somewhere between 25 and 37%.
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Next, predictions of receptor occupancy when diazepam is used in a “seizure reversal”
scenario, were simulated based on the experiments performed by Kapur and Macdonald (1997).
These researchers induced stage 5 seizures in all rats by pilocarpine iv. Rats were then treated
with increasing doses of diazepam at either 10 or 45 min post seizure onset (see Figure 4-3). The
percent of rats observed to be seizure free within 5 min of diazepam was counted as the response.
Therefore, we simulate GABAA receptor trafficking, using the SE parameters established in
Chapter 2, to establish the change in surface receptor levels at the time when the anticonvulsant
response was actually measured (15 and 50 min post SE onset). For comparison with Igari’s
study, these endpoints were also simulated for conditions where diazepam is given at time zero of
seizure onset (when 100% of receptors are available). In addition, the dose 1.2 mg/kg was also
added to these predictions, as it was the lowest dose shown by Igari when diazepam was
administered 3 minutes prior to seizure induction.) Simultaneously, simulations of brain
concentrations 5 min after each dose of diazepam listed in Figure 4-3, including 1.2 mg/kg, were
performed. The 5 min timepoint represents the time when the “effect” or percent seizure free
were counted. Finally, receptor occupancies were predicted from these simulations and
illustrated in Figures 4-4.

0

10

15

45 50

@10 min - 2, 7.5, 10, 20 mg/Kg DZ
@45 min - 20, 30, 50, 100 mg/kg DZ

Figure 4-3. Experimental design of Kapur and Macdonald (1997). Seizures were induced at
time zero and either 10 or 45 min later, increases doses (shown) were administered and animals
were observed for 5 min for signs of seizures.
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Figure 4-4. Model predicted brain concentrations five minutes post iv injection of 1.2, 2.0, 7.5,
10, 20, 30, 50 and 100 mg/kg diazepam in rats vs. changing percent receptor occupancy when the
diazepam doses are delivered either 0, 10 or 45 minutes post onset of SE. The black dotted linse
shows indicates the predicted brain concentrations at 37% receptor occupancy, the reported
occupancy for seizure prevention when diazepam is delivered at time zero of seizure initiation
(based on Igari et al.1985). Red circles indicate the predicted brain concentrations and
occupancy levels from diazepam doses reported by Kapur and Macdonald (1997) to reverse
seizure activity, when delivered 10 and 45 minutes into SE. The blue, red and green dashed lines
indicate the changing maximum percent of original number of available receptors at times 0, 10
and 45 min post onset of SE. Arrows indicate the brain concentrations required to for 55%
occupancy.

Receptor occupancy was also simulated for humans, by using the human physiological
and metabolic parameters listed in Chapter 3. Parameters driving GABAA receptor trafficking
were assumed to be the same as those derived from rat hippocampal cultures under SE conditions.
In addition, the same Kd unbound (in vivo) was used. GABAA receptor dissociation constants of various
BZs in rat and man have been determined by in vitro experiments using brain tissue homogenate
by Okada (1980). The values of the dissociation constant of each BZ in human brain were almost
the same as that in rat brain, suggesting that any species difference in the receptor binding affinity
of BZs is very small. The resulting predictions in human are shown in Figure 4-5.
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Figure 4-5. Model predicted brain concentrations five minutes post iv injection of 1.2, 2.0, 7.5,
10, 20, 30, 50 and 100 mg/kg diazepam in humans vs. changing percent receptor occupancy when
the diazepam doses are delivered either 0, 10 or 45 minutes post onset of SE. The two arrows
indicate the brain concentrations required to achieve 55% receptor occupancy when diazepam is
administered either 10 or 45 min post onset of SE.

Table 4-1. Percent Receptor Occupancy & Brain Concentration (mg/kg) Required for
Maximum Anticonvulsant Effect
Time after
seizure onset

% Occupancy for
Max Effect

0 min
10 min
45 min

37%
55%
55%

[Brain] Required
for EC”100”
Rat
1.2
10.0
85

[Brain] Required
for EC”100”
Human
>0.5
2.9
11.0

HumanEC”100”
Rat EC”100”
>0.42
0.29
0.13

Conclusions
Relating fractional receptor occupancy to efficacy is an indirect but reliable way to assess
relative intrinsic efficacy of anticonvulsants. The model approach demonstrated here suggests
that the reported level of GABAA receptor occupancy required for preventing seizure onset
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(approximately 37%) is insufficient to arrest on-going seizures. Approximately 55% occupancy
of the original number of receptors is predicted to correspond with the lowest successful
diazepam dose, found to be 100% successful for seizure reversal when administered 10 min into
SE in Kapur et al.’s study (Figures, 4-4 and 4-1). Interestingly at 45 minutes into SE, 55%
occupancy also corresponds with the dose observed to result in 100% seizure free rats (100
mg/kg) (see Figure 4-1). These results suggest that while receptor occupancy may not be a
consistent biomarker for both seizure prevention and seizure reversal, it does appear to be a
consistent biomarker for seizure reversal. The brain concentrations required to achieved 55%
occupancy (the “EC100”) increases dramatically between 10 and 45 minutes post SE onset,
requiring almost a 9 and 5 fold increase for the rat and human, respectively.
Fifty five percent occupancy for seizure termination appears reasonable, when compared
with other measured values from pharmacological studies on the effects of diazepam and other
BZs, administered alone. Facklam et al. (1992) demonstrated that 30-50% GABAA receptor
occupancy by diazepam in vivo results in sedative effects. They also demonstrated that in vitro
35% occupancy enhanced chloride current by 25%. Sixty percent occupancy by the BZ,
flumazenil, has been shown to induce unconsciousness (Amrein et al., 1988).
Assuming diazepam binding with each individual GABAA receptor results in the same Clinflux, one may logically assume that the same number of occupied receptors (percent of original
receptors) would be needed to achieve the same results. The predicted need for an 18% increase
in receptor occupancy between seizure prevention and seizure reversal reflects more than a
diminishing number of available GABAA receptors. This is suggested by the model, given total
saturation of available receptors was not achieved at the doses experimentally determined to be
successful at 10 min post SE onset. Likewise at 45 min, only the highest dose begins to approach
receptor saturation. In addition to reduced GABAA receptors, changes in the expression of other
receptors that influence membrane potential also appear to be responsible for the increase in
therapeutic threshold. While BZ-sensitive GABAA receptor numbers are declining, NDMA and
67

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are increasing at
excitatory synapses, aggravating the loss of inhibitory GABAergic signals, by making the
membrane more excitable (Naylor, 2010). AMPA antagonists have demonstrated effectiveness in
arresting SE when administered 1 h after exposure to the NA, soman (Figueiredo et al., 2011). It
is estimated that NMDA mEPSCs increase in amplitude 23% during SE, with an estimated 38%
increase in the number of postsynaptic NMDA receptors at 1 h by mean-variance analysis
(Naylor, 2010). Non-NMDA receptors also show an increase in number at synaptic sites, with SE
(19% amplitude increase with estimated 22% increase in postsynaptic receptor numbers; p <
0.001) (Prybylowski et al., 2002). Therefore, the surface accumulation of AMPA and NMDA
receptors further upsets a diminishing GABAA receptor inhibitory mechanism for ongoing seizure
activity and a vicious cycle ensues. Early loss of synaptic inhibition through receptor
internalization and/or desensitization upsets a balance with excitation and explains the
pharmacoresistance to BZs.
Accounting for the metabolite DMD did not significantly impact receptor occupancy
predictions from these acute simulations in either rat or human. This is because the metabolite
concentrations achieved did not exceed those of the parent compound in the acute scenarios
simulated here. At the early time points when diazepam efficacy was assessed,
desmethyldiazepam concentrations were close to an order of magnitude lower than those of
diazepam (Figure 4-2). However, the inclusion of this major metabolite would be of relevance if
simulating longer term treatment of SE or epilepsy, or possibly in cases of repeated dosing to
arrest seizures. The longer half life of DMD would result in its build up in fat and brain.
Therefore, the time-course of net receptor occupancy in brain would be longer than would be
attributed to diazepam alone. The diazepam metabolites can play an important role in net
receptor occupancy and overall pharmacological activity.
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Chapter 5. Discussion

This dissertation presents a computational approach, combining in vitro and in vivo data,
for examining the rapid loss of diazepam’s efficacy as an anticonvulsant, with increasing duration
of SE. A number of recent studies indicate that the pharmacoresistance seen during SE can to a
large degree be attributed to rapid internalization of BZ-sensitive GABAA receptors (Naylor et
al., 2005; Goodkin et al., 2005; Feng et al., 2008). To investigate the roles that GABAA receptor
dynamics together with diazepam’s pharmacokinetics play in this time-dependent
pharmacoresistance PBPK/PD modeling is used. Physiologically-based
pharmacokinetic/pharmacodynamic modeling allows for the integration of various data sets in a
mechanistically meaningful way. More importantly, the physiological and biochemical basis of
the model’s parameterization allows for extrapolation across species, doses and dose routes.
Therefore, the approach demonstrated here is especially well suited for evaluating the efficacy of
anticonvulsants, since controlled clinical trials cannot be readily performed for ethical reasons.
Human data tends to be anecdotal and extremely variable from case to case, with seizure cause
and time of onset being uncontrolled variables.
The PBPK portion of this modeling effort predicts the changing concentrations of
diazepam and its major metabolite, DMD, in the brain and several other tissues in rats and
humans. The simulated concentrations were validated against measured tissue kinetic data in the
rat as well as plasma data in humans. The brain concentration kinetics or “biophase” kinetics is
an important determinant in the time course and intensity of the drug’s CNS effects. The PD
components predict the temporal pattern of the drug’s pharmacological effect. In this case, the
changing surface expression of the targeted BZ-sensitive GABAA receptors, both constitutive and
during on-going seizures, is simultaneously linked with PBPK simulations of brain diazepam
69

concentrations to predict in vivo GABAA receptor occupancy when the drug is administered at
different times following the onset of SE.
Equal doses (in mg/kg) of diazepam result in higher circulating levels in human plasma
than that of rats, due to a greater extent of binding to plasma proteins and reduced metabolic
clearance in humans. However, the increase in plasma binding also results in lower concentration
in brain and other tissues in humans. While, the major metabolite DMD is centrally active, it
does not significantly contribute to receptor occupancy in the acute dosing scenarios predicted
here. The simulations here predict receptor occupancy resulting only a few minutes after
diazepam administration. During these early time points, DMD concentrations are nearly an
order of magnitude lower than those of diazepam in both rats and humans. If the model is used in
the future for simulating receptor occupancy from repeated doses of diazepam, the metabolite is
expected to contribute significantly, as concentrations build up. Also if the model is used to
simulate dosing in individuals who are poor metabolizers, DMD may exceed diazepam levels in a
relatively short period. To account for such individuals, as well as variations in the general
public, future iterations should include variability analysis of the model’s most sensitive
parameters. Variability analysis would also enhance the model’s usefulness by predicting a range
of physiologically reasonable concentrations that reflects the population diversity.
To account for the changing surface expression of BZ-sensitive GABAA receptors during
SE, a simplified model which treats the dendritic spine as a single cell was developed. The
trafficking of the receptors between the postsynaptic and the other regions of the dendritic spine
were described by rate constants. Receptor trafficking is a complex process involving multiple
proteins and processes. Therefore, for simplicity, each rate constant represents a composite of
such processes, optimized to produce results consistent with the experimental data used in this
analysis. Overall, measured trafficking rates observed across a number of different in vitro SE
models and our SS analysis of the model’s parameters (which was based on measured receptor
densities) were consistent, instilling confidence in the model’s final parameters. Minor
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differences in rates seen between studies likely arose from differences in cell types (neuronal vs.
recombinant cells), labeling techniques or the effects of the label itself on the receptor. An
example of such a difference was the exocytosis rate, kex, observed between neuronal and
recombinant cell types. Receptor internalization and exocytosis measured in neuronal cultures
(Joshi and Kapur, 2009) were consistent with the SS analysis, whereas the kex, was nearly double
in transfected HEK cells. The difference may well be due to the lack of synaptic clustering and a
lower surface receptor density in non-neuronal cultures. Therefore, while neuronal and
recombinant cells share similar rates of constitutive endocytosis, recombinant cells may display a
higher rate of exocytosis in an attempt to maintain stable surface levels. For this reason, the
parameters established from neuronal cultures were used in the final PD model, as they more
accurately reflect in vivo dynamics.
Together, the trafficking model and the studies used to parameterize the receptor
trafficking model demonstrate that the surface stability of GABAA receptors can be dynamically
and specifically regulated, enabling neurons to modulate cell surface receptor number upon the
appropriate cues, such as activity. The kinetics of the model depends upon various composite
trafficking parameters that could be targets of second messenger pathways activated during
seizures. The model was used to explore the consequence of targeting different parameters to see
how these parameter changes can reproduce a wide range of experimental data. To simulate SE
conditions, increases in the rates depicting endocytosis, kin, and the release from scaffolding
proteins, ka, appeared sufficient to describe in vitro SE models in cultured neurons, using high K+
or low Mg2+. The increased level of internalization seen from the in vitro data at 1 h agreed with
ex vivo measurements from pilocarpine challenged rats. Therefore, there is confidence in the
receptor trafficking model’s parameterization for depicting changes in GABAA receptor levels in
vivo.
Why there is a rapid "down regulation" of GABAA receptors at the synapse during SE is
indeterminate, being contrary to protective homeostatic mechanisms. However, the ability of
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neurons to rapidly modulate GABAA receptor density at inhibitory synapses upon excitatory
activity by regulating synaptic clustering and endocytic processes may have evolved as an
important mechanism for learning. At the onset of long term potentiation (LTP), excitatory postsynaptic potentials (EPSPs) are more likely to elicit an action potential in the postsynaptic cells if
there is a reduction in IPSPs (Wang and Stelzer, 1996). Bannai et al.,(2009) hypothesized that
activity-dependent neuronal disinhibition may be an underlying mechanism for the induction of
LTP, stating that “lateral diffusion, regulated through receptor-scaffold interactions, provides a
simple mechanism for rapid and reversible activity dependent modulation of synaptic strength.
During SE, the antihomeostatic excitation-inhibition regulation may be defective, resulting in
exaggerated loss of inhibition.” Novel pharmacological targets for SE as well as an improved
understanding of the mechanisms behind learning and memory may be elucidated from
quantitative studies on the details controlling receptor diffusion dynamics.
Future expansion of the receptor trafficking portion of the model may include the BZinsensitive receptors, as more data becomes available. The BZ-insensitive GABAA receptor
subtypes, containing the δ subunit, are not rapidly internalized during SE and actually
demonstrate a trend toward increased expression at the synapse (Joshi and Kapur, 2009). Drugs
that bind to these subtypes, such as neurosteroids, could represent potential therapeutics that
could be used in combination with, or instead of standard BZs.
The model may also be expanded to explore altered receptor kinetics resulting from
chronic exposure to BZs, the phenomenon known as tolerance. Investigations in both primary
neuronal and cell cultures and in vivo have demonstrated concentration- and time-dependent
reductions in the efficacy of GABA to enhance inhibition with chronic BZ exposure (Wong et al.,
1994), involving either post-translational modification of GABAA receptor proteins or changes in
subunit stoichiometry.
It has been reported that approximately 37% receptor occupancy is required to prevent
onset of behavioral seizures in rats when diazepam is administered minutes before a
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chemoconvulsant (Igari et al., 1985). In mice, full protection against pentylenetetrazol-induced
seizures has been demonstrated by approximately 30% occupancy (Paul et a., 1978). These
studies, however, reflect idealized scenarios in which the therapeutic is given before, or at the
same time as the onset of seizures (seizure prevention rather than seizure reversal). Realistically,
the scenario is much different. Epidemiological studies have shown that time to seizure treatment
in the U.S. varies broadly with only about 41% of all patients receiving their first antiepileptic
drug within 30 minutes (Pellock et al., 2004). Our model predicts a required 55% occupancy of
the original number of receptors for termination of on-going behavioral seizures. This value
appears to be a consistent requirement after the onset of SE, as it delineates the percent of
receptor occupancy achieved at the lowest doses identified as successful in terminating seizures at
both 10 and 45 min into SE, in Kapur and Macdonald’s 1997 study. Although, this degree of
receptor occupancy is achieved at a higher degree of saturation of the fewer remaining receptors
at 45 min than 10 min, necessitating a correspondingly higher brain concentration (see Figure 44). The model also suggest that if SE continues for much longer than 45 min, no dose of
diazepam will be able to fully terminate behavioral seizures because there will not be enough
receptors available to achieve 55% occupancy. The GABAA trafficking model predicts a 45%
loss in surface receptors at 1h into SE. Based upon measured receptor occupancy levels for
various effects of diazepam, 55% occupancy lies somewhere between levels reported to cause
sedation (30-50% occupancy) (Facklam et al.,1992b) and unconsciousness (60% occupancy)
(Amrein et al., 1988). In principle the model could be used to optimize BZ dosing regimens
(determining the adequate dose depending on time since seizure onset).
The reason for an 18% increase in the therapeutic threshold for receptor occupancy from
prevention to reversal modes is likely to be attributed to more than just a loss of GABAA
receptors. There is also an increase in excitatory transmitters and receptors (Naylor, 2010).
NDMA and AMPA receptors are increasing at excitatory synapses, aggravating the loss of
inhibitory tone associated with GABAergic losses. These rapid receptor changes indicate that
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several therapeutic options for treating SE exist. A combination of agents that block either
AMPA or NMDA receptors and enhance GABAA receptors may provide the most efficacious
route to restore inhibitory tone to seizing hippocampal networks. Agents that target the BZinsensitive extrasynaptic GABAA receptor may also be effective, given these are not rapidly
internalized during SE. Drugs that target scaffolding proteins in a way that might enhance the
stability of GABAA receptors at the synapse, could possibly restore inhibitory tone. Therefore,
many possibilities for novel therapeutics exist. However, much caution must be taken in the
search for suitable agents that alter the expression or functionality of neuroreceptors, especially
given that the receptors’ abilities to rapidly modulate neuronal messages is critical for normal
brain functioning.
The modeling approach demonstrated here provides a potential means of extrapolating
dose response and optimizing the therapeutic windows of similar-acting drugs. This model
specifically, can be expanded many ways, possibly offering insights into a larger collection of
GABAA receptor trafficking data. The ODE model could also be modified to explore the
trafficking of different receptors and the pharmacodynamic interactions of drugs or chemicals that
target them. For example, the model could be extended to describe the simultaneous trafficking
of AMPA and NMDA receptors during SE and ultimately used to identify a superior therapeutic
“cocktail”, which targets each of these receptors in a quantitatively optimal manner. Such a
model also would have applications for exploring situations, unrelated to seizures, such as
synaptic plasticity, learning and memory. Finally, a future endeavor for this type of modeling
may be to relate it to ion transport, providing a link to hyperpolarization and depolarization
models.
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